DRANZCOG/Obstetrics Flashcards

1
Q

Risk factors for shoulder dystocia

A

At least 50% of shoulder dystocias have no identifiable risk factors!

Antenatal (5):

  • previous shoulder dystocia
  • macrosomia
  • maternal DM
  • maternal obesity
  • post-term pregnancy

Intrapartum (5)

  • prolonged 1st stage
  • prolonged 2nd stage
  • labour augmentation
  • instrumental delivery
  • post-term pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Consequences of a shoulder dystocia

A

Neonatal (4)

  • brachial plexus injury (Erb’s palsy)
  • fractures (humeral and clavicular)
  • hypoxia
  • stillbirth

Maternal (6)

  • PPH
  • severe vaginal and perineal trauma (3rd and 4th degree tears)
  • cervical tears
  • uterine rupture
  • bladder rupture
  • psychological distress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When to suspect shoulder dystocia

A
  • prolonged birth of face and chin
  • head emerges and retracts against the perineum (turtle sign)
  • fetus fails to undergo external rotation
  • the anterior shoulder does not emerge with routine axial traction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Reassuring features on intrapartum CTG

A

Baseline FHR 110-160 bpm
Baselines variability of 5-25 bpm

No decels OR early decles OR variable decelerations with NO concerning features for less than 90 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Non-reassuring features on intrapartum CTG

A

Baseline FHR 100-109 OR 161-180
Variability <5 for 30-50 minutes OR >252 for 15-25 minutes

Variable decels WITHOUT concerning characteristics for 90 minutes +
OR
variable decels with any concerning characteristics in <50% of contractions for 30 minutes +
OR
variable decels with any concerning characteristics in OVER 50% of contractions for LESS than 30 minutes
OR
Late decels in >50% of contractions for <30 minutes with no maternal or fetal clinical risk (e.g. signficicant mec, PV bleeding etc. )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ABNORMAL features of an intrapartum CTG

A

Baseline FHR <100 or >180

Variability <5 for more than 50 minutes 
OR 
>25 for more than 25 minutes
OR
Sinusoidal

Variable decels with any concerning characteristics in >50% of contractions for 30 minutes (or less if maternal of fetal clinical risk factors)
OR
Late decels for 30 minutes
OR
Acute bradycardia, or single prolonged deceleration lasting 3 minutes or more

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Concerning characteristics of variable decelerations

A
>60 seconds duration
Reduced baseline variability within the deceleration
Failure to return to baseline
Biphasic (W) shape
No shouldering
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Interpretation of normal v suspicious etc. intrapartum CTG

A

Normal = all reassuring features

Suspicious = 1 non-reassuring feature + 2 reassuring features

Pathological - 1 ABNORMAL feature OR 2 non-reassuring features

Urgent intervention required: acute bradycardia, or single prolonged deceleration 3+ minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Features to assess when describing decelerations on CTG

A
  • timing related to peak of contractions
  • duration of individual decels
  • if FHR returns to baseline
  • how long have decelerations been present
  • do they occur with >50% of contractions
  • presence of a biphasic (W) shape)
  • presence or absence of shouldering
  • normal or reduced variability WITHIN the deceleration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Definition of antepartum haemorrhage

A

Bleeding from the genital tract after the 20th week of pregnancy, and before the onset of labour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Epidemiology of antepartum haemorrhage

A

Occurs in 2-5% of all pregnancies

Up to 20% of preterm babies are born in association with APH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Causes of antepartum haemorrhage

A
  • (non-vaginal e.g. PR bleed)
  • Distal genital tract/gynae causes
  • cervical (ectropion, polyp, cervicitis, cervical dilatation, cervical incompetence)
  • Placental (praevia, abruption, abnormal placentation, abnormal shape, marginal bleed)
  • Uterine (rupture)
  • Foetal (vasa praevia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Relevant history to obtain in woman presenting with antepartum haemorrhage

A

Gestation
Location of placenta
Bleeding: time of first bleed, pattern, previous APH (this pregnancy or previous)
- Potential causes (postcoital, trauma, exertion)
- CST results
- Pain (site, commencement, frequency, strength, duration)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Maternal assessment in antepartum haemorrhage

A

ABCs
Abdominal palpation (gently) for SFH, lie, presentation, tenderness
USS: placental location if not known
Blood loss (amount, colour, consistency)
Uterine activity and consistency
Bloods (CBE, Group and save +/- crossmatch if heavy bleeding, coagulation profile, Kleihauer if Rh negative)
Speculum examination - swabs (STI, LVS, HVS) and consider CST if not performed in the last 3 months + clear cervical bleeding

(CTG for fetal assessment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Epidemiology of placental abruption

A

1% of births
- 20-35% of these are concealed, rest are revealed

Perinatal mortality rate of 11.9%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Risk factors for placental abruption

A

Maternal:

  • hypertension
  • thrombophilias
  • increased parity
  • poor nutrition
  • previous abruption (~10% risk of recurrent)
  • cigarette smoking
  • substance abuse (esp. cocaine)

Uterine factors:

  • Prolonged ROM (especially if PPROM)
  • chorioamnionitis
  • severe IUGR
  • polyhydramnios (sudden decrease in uterine volume post SROM)
  • Multiple pregnancy (sudden decrease in uterine volume following delivery of twin 1)
  • abdominal trauma
  • ECV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Presentation in placental abruption

A

Vaginal bleeding associated with PAIN, usually very distressed (out of proportion to amount of bleeding)

Usually dark, non-clotting b lood
Abdominal pain Or uterine contractions/tenderness/irritability
Can be associated with faint/collapse or haemorrhagic shock

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Complications/associations of placental abruption (9)

A
  • preterm labour
  • foetal compromise
  • uterine irritability (>5:10 contractions)
  • coagulopathy
  • disseminated intravascular coagulopathy
  • postpartum haemorrhage
  • renal failure
  • Acute tubular necrosis (from hypovolaemia and DIC)
  • perinatal mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the most common OBSTETRIC cause of coagulopathy

A

Placental abruption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Management in placental abruption

A
  • IV access
  • IDC and fluid balance
  • Close maternal obs + CTG
  • Resuscitation as indicated
  • Urgent Group and cross-match, CBE, Coagulation studies, D-dimer, fibrinogen levels, EUC, LFT
  • Anti-D prophylaxis for Rh neg (+ Kleihauer)
  • delivery (LSCS if acute fetal compromise or other indication - be prepared for precipitous labour)
  • prepare for increased risk of PPH
  • examine placenta and send for histopathology
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Perineal injury classifications

A

1st deg: injury to skin only

Second degree: injury to perineal muscles but NOT the anal sphincter

3rd degree: injury involving anal sphincter complex

3a: <50% external anal sphincter thickness torn
3b: >50% external anal sphincter rotn
3c: Internal anal sphincter town

4th degree: injury involving anal sphincter complex AND anal epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Appropriate analgesia to use for perineal repair

A

1% lignocaine +/- adrenaline (or equiv)

Without adrenaline is preferred for labial tears to reduce risk of tissue ischaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Preferred suturing technique for vaginal wall and muscle layer

A

Continuous, non-locked

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Approximate epidemiology of perineal injury

A

25% of NVD: intact perineum
12% episiotomy
40% tear requiring repair

Other minor tears that don’t require repair

Women with epidural higher risk of instrumental delivery and associated perineal morbidities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Antenatal methods to protect against perineal morbidity

A
  • Perineal massage 1-2x/week from 35/40
  • Pelvic floor muscle training for women (Continence Foundation of Australia)

Insufficient evidence to recommend raspberry leaf tea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Intrapartum care to protect from perineal morbidity

A

No specific position or pushing technique recommended

Warm compresses and perineal massage: lowers risk of 3rd and 4th degree tears

During crowning:

  • minimise active pushing following crowning to ensure slower descent of head. - If rapid, consider counter pressure on foetal head if appropriate
  • maximise flexion to help reduce presenting diameter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

When to use episiotomy

A

Imminent perineal tear
OR
High risk of severe laceration:
1. Soft tissue dystocia
2. Foetal compromise indicating expedited delivery
3. Instrumental delivery (not always required for vacuum)
4. History of female genital mutilation
5. Past history of pelvic floor repair or third-degree tear

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Anatomy involved in episiotomy

A

Vaginal mucosa
Perineal skin
Bulbocavernosus muscle
Transverse perineal muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Technique to perform episiotomy

A
Appropriate analgesia (e.g. 1% lignocaine)
Incision 3-5cm length from the fourchette ad 60-80 degree angle from midline (will become 45 degrees following delivery, loss of distension)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Immediate postpartum perineal care

A

Repair if indicated
Rectal NSAID unless PPH if torn
If tear within close proximity of urethra, consider indwelling catheter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Postpartum perineal care recommendations

A

Cold packs (10-20 minute intervals) first 1-3 days
PRN PO paracetamol and NSAID
Urinary alkalinisers
Avoid opioids

Fibre rich, balance diet, adequate hydration

Support perineal wound when coughing or defecating
Correct toileting position
Avoid constipation
Wash and pat dry post toileting
Shower at least daily
Check wound daily with hand mirror

Pelvic floor muscle training for women

Avoid sitting/propped positions (dependent perineal oedema)
Avoid increased intra-abdominal pressure for 6-12 weeks (e.g. straining, lifting etc.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Postpartum perineal care methods that lack evidence currently

A

Sitz baths
Perineal ultrasound for perineal pain or dyspareunia
Topical anaesthetics
Ray lamps
Donut cushions (may lead to more dependent oedema)
Herbal remedies e.g. arnica

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Anatomy of the Bartholin glands

A

Paired glands located in labia minor at 4 and 8 o’clock positions
Approx 5mm in diameter
Secrete mucus into 2.5cm ducts which emerge either side of vagina, inferior to the hymen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Pathophysiology of Bartholin gland cyst

A

Nonspecific inflammation or trauma -> obstruction of opening of duct -> distension of gland or duct

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Pathophysiology of bartholin gland abscess

A

Either secondary to infected cyst, or a primary gland infection
Usually polymicrobial
Rarely caused by STIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Epidemiology of Bartholin gland disease

A

2% of women of reproductive age will experience swelling of at least one Bartholin gland
Typically in women 20-30y
Rare in women >40y (malignancy should be considered)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Clinical presentation of Bartholins cyst

A

Painless (unless very large) labial swelling, usually unilateral

No signs of surrounding cellulitis
Discharge if has spontaneously ruptured will be non-purulent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Clinical presentation of Bartholin’s Gland Abscess

A

Acute painful unilateral labial swelling
Dyspareunia
Pain with walking and sitting
Sudden relief of pain followed by discharge (suggests spontaneous rupture)

Can occur spontaneously or on history of a painless cyst

Very tender with surrounding erythema and oedema
may have surrounding cellulitis
Purulent discharge if spontaneously ruptured

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Management of Bartholin Gland Disease

A

Asymptomatic uncomplicated cyst:
- Sitz baths 3x per day for several days (may induce resolution +/- rupture)

Abscess:
Incision and drainage +/- marsupialisation
Antibiotics only required if significant surrounding cellulitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Definitions of postpartum haemorrhage:

A

Traditionally primary postpartum haemorrhage = blood loss >500mL in first 24h
Minor: 500-1000mL
major: >1000mL (moderate 1000-2000mL, severe >2000mL)

note that some centres consider PPH as >600mL following NVD or >750mL following LSCS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Risk factors for PPH

A

2/3 of women who have PPH have no risk factors identified

Background risk:

  • PPH in previous pregnancy
  • grand multiparity (4+)
  • Nulliparity
  • Advanced maternal age (>35y)
  • known coagulopathies or liver disease
  • obesity
  • previous LSCS

Antenatal complications:

  • multiple pregnancy
  • antepartum haemorrhage (esp placental abruption or previa)
  • known placenta accreta
  • anaemia
  • pre-eclampsia
  • macrosomia
Intrapartum:
- need for/use of oxytocics
- prolonged labour (especially 2nd stage)
Pyrexia in labour
operative delivery
Episiotomy
Placental retention
Shoulder dystocia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Causes of PPH (general groups and %)

A

Tone (70%)
Trauma (20%)
Tissue (10%)
Thrombin (<1%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Atonic causes o PPH

A

Uterine atony (e.g. physiological or prolonged 3rd stage)
Over-distended uterus (polyhydramnios, multiple gestation, macrosomia)
Uterine muscle exhaustion (rapid labour, prolonged labour, high parity, augmentation with oxytocin)
Intra-amniotic infection (PROM >24h)
Drug-induced (magnesium, nifedipine, salbutamol, GA)
Functional or anatomical distortion of the uterus (fibroids, placenta praevia, uterine abnormalities, bladder distention)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Tissue causes of PPH

A

Retained products
Abnormal or adherent placenta
Retained cotyledon or succenturiate lobe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Trauma causes of PPH

A
Lacerations to cervix, vagina, perineum (precipitous labour, operative delivery)
Uterine rupture (high parity, fundal placenta)
Extensions/lacerations at LSCS (malposition, deep engagement)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Thrombin causes of PPH

A

Non-obstetric abnormalities (Haemophilia, vWd, hereditary coagulopathies, liver disease)
Acquired in pregnancy (ITP, PET, DIC, IUFD, severe infection, abruption, AFE)
Therapeutic anti-coagulation (e.g. clexane for VTE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Blood loss and signs of Class I hypovolaemic shock in late pregnancy

A
15% (1000mL)
RR: normal
HR: <100
BP: Normal
Mental state: anxious
Urine output: normal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Blood loss and signs of Class II hypovolaemic shock in late pregnancy

A
15-30% (1300mL)
RR: 20-30
HR: >100
BP: Normal/increased diastolic
Mental status: anxious/confused
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Blood loss and signs of Class III hypovolaemic shock in late pregnancy

A
30-40% (2000mL)
RR: 30-40
HR: >120
BP: reduced systolic and diastolic
Mental state: confused/agitated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Blood loss and signs of Class IV hypovolaemic shock in late pregnancy

A
>40% (2700mL)
RR: >40
HR: >140
BP: decreased systolic and diastolic
Mental state: lethargic
Negligible urine output
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Indications for intrapartum antibiotics (general)

A
  • prevention of early onset GBS infection
  • women at risk of chorioamnionitis, or where infection is suspected (temp >38 on one occasion or >38.5 on two occasions)
  • women with cardiac lesions susceptible to infective endocarditis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Relative contraindications to amniotomy

A
  1. Maternal HBV, HCV, HIV, HSV infection - minimise risk of vertical transmission to foetus
  2. high and mobile presenting part
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Factors to assess progress in the second stage of labour

A

Flexion
Rotation
Descent of head

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Risk factors for pre-eclampsia (11)

A
Antiphospholipid syndrome
Previous history of PET
Pre-existing diabetes
Nulliparity
Multiple pregnancy
Family history of PET
Obesity (BMI >30)
Systolic BP >130 <20/40
Diastolic BP >80 <20 weeks
Age >40y
Overweight (BMI 25-29.9)
Underlying renal disease
Chronic autoimmune disease
Inter-pregnancy interval >10y
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Early onset pre-eclampsia definition (i.e. gestation)

A

Onset <32 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Systems which can be involved in pre-eclapmsia

A
Neurological
Pulmonary
Haematological
Hepatic
Renal
Uteroplacental
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Requirements for renal dysfunction in diagnosis of PET

A

Proteinuria >300mg/24h PR PCR >30
Creatinin >90
Oliguria <80mL/4h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Criteria for hameatological end organ dysfunction in diagnosis of PET

A

Platelets <100
Haemolysis (shistocytes or red cell fragments on film, raised bilirubin, raised LDH >600, reduced haptoglobin)
Disseminated intravascular coagulopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Criteria for hepatic end organ dysfunction in diagnosis of PET

A

Increased transaminases

Severe epigastric and/or RUQ pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Criteria for neurological end organ dysfunction in diagnosis of PET

A
Convulsions (=eclampsia)
Hyperreflexia with sustained clonus
Persistent, new headache
Persistent visual disturbances (photopsia, scotomata, cortical blindness, posterior reversible encephalopathy syndrome, retinal vasospasm)
Stroke
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Criteria for pulmonary end organ dysfunction in diagnosis of PET

A

Pulmonary oedema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Criteria for uteroplacental end organ dysfunction in diagnosis of PET

A

Fetal growth restriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Prophylaxis for women at risk of hypertensive disorders of pregnancy

A
Aspirin 50-150mg daily from diagnosis of pregnancy (aim for <16 weeks - 37 weeks)
Calcium supplementation (esp if high risk and low calcium intake diet)
1.5g/day from <20/40 until delivery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Investigations in assessment for hypertensive disorders of pregnancy

A

Urine PCR
CBE (Hb, PLT)
EUC
Urate (not actually in diagnostic criteria)
LFTs
Coagulation studies (depending on severity of presentation)

USS: foetal growth, AFI, umbilical artery doppler assessment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Definition of SEVERE pre-eclampsia

A

BP >/= 160/110 with proteinuria

OR
BP 140/90-159/109 with at least ONE of the following
- severe headache
- visual disturbances
- severe pain below ribs OR vomiting
- papilloedema
- clonus (3+ beats)
- liver tenderness
- HELLP syndrome
- PLT <100
- abnormal liver enzymes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Antihypertensives that can be considered during pregnancy

A
Methyldopa
Labetalol
Nifedipine XR
Nifedipine IR
Hydralazine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Antihypertensives for use in acutely lowering severe hypertension of pregnancy (and dose)

A

Nifedipine IR 10-20 mg repeated in 30 minutes if BP still above threshold

Labetalol 200mg PO repeated in 30 minutes if not below threshold OR 20mg IV with repeat doses 40-80mg every 10 minutes until BP controlled (max 4 dose)

Hydralazine f not controlled by nifedipine - 5mg IV bolus/5 minutes, repeated every 20 minutes until BP controlled (max 30mg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Antihypertensives and doses for sustained BP control in pregnancy

A

Methyldopa 250-750mg every 8 hours

Labetalol 100-400mg every 8 hours

Nifedipine XR 30-60mg BD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Side effects of antihypertensives in pregnancy

A

Methyldopa:

  • depression
  • dry mouth
  • sedation
  • blurred vision

Labetalol:

  • bradycardia (maternal and fetal)
  • bronchospasm
  • headache
  • nausea
  • scalp tingling
Nifedipine:
- constipation
- severe headache in first 24h
- peripheral oedema
tachycardia
- flushing

Hydralazine:

  • flushing
  • headache
  • nausea
  • tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Onset of action of antihypertensives used to acutely lower blood pressure in pregnancy

A

Labetalol: peak effect within 5 minutes of each dose

Nifedpine IR: onset 30-45 minutes

Hydralazine: onset of action 20 minutes

(Methyldopa only used for sustained BP control, has slow onset over 24 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

Contraindications to specific antihypertensives used in pregnancy

A

Methyldopa: depression

Labetalol: Asthma/COAD

Nifedipine: Aortic stenosis

Hydralazine:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Treatment of severe pre-eclampsia

A
  1. Stabilise
    - control BP (labetalol, nifedipine IR or hydralazine)
    - MgSO4 loading + maintenance dose)
  2. Monitor
    - vital signs
    - urine output/strict fluid balance
    - neurological status
    - clotting factors
    - fetal conditions (CTG)
  3. Plan for labour/birth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Indications for birth in women with pre-eclampsia (13)

A

Maternal:

  • > 37/40 gestation
  • falling PLT count
  • intravascular haemolysis
  • HELLP syndrome
  • deteriorating LFTs
  • deterioration renal function
  • persistent neurological symptoms
  • persistent epigastric pain, nausea or vomiting with abnormal liver function
  • pulmonary oedema

Fetal:

  • placental abruption
  • severe fetal growth restriction
  • non-reassuring fetal status
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Additional considerations of management of PET

A

Thromboprophylaxis

Monitoring of PLT at least daily (peripartum bleeding complications nor significantly increased until PLT <50)
AND monitoring for intravascular haemolysis (CBE, blood film, LDH, haptoglobins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Pregnancy complications associated with bipolar affective disorder (i.e. more likely in BPAD than in general population)

A
Pre-eclampsia
Gestational diabetes
Gestational hypertension
Antepartum haemorrhage
Severe fetal growth restriction
Neonatal morbidity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Pregnancy complications associated with schizophrenia (i.e. more likely in pregnant schizophrenics than in general population)

A

Pre-eclampsia

Gestational hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Pregnancy complications with a higher risk in borderline personality disorder

A
Gestational diabetes
PPROM
Chorioamnionitis
VTE
Caesarean section
Preterm birth

High rates of substance abuse, referral to child protective services, anticipation of traumatic delivery and frequent request of early delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Optimising use of nitrous oxide

A

Start inhalation 30-50 seconds prior to contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Dosages of nitrous oxide

A

Start at 30% N2O, max of 70% N2O to prevent hypoxia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Adverse effects of nitrous oxide

A

If used with oxygen (as always should be in labour):

  • nausea
  • vertigo
  • megaloblastic anaemia

N2O alone:

  • increased maternal heart rate
  • respiratory depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Contraindications to nitrous oxide use

A

Inability to hold mouthpiece
Impaired consciousness
Impaired oxygenation (e.g. respiratory disease)
Women who have received excessive amounts of other sedating medications
Vitamin B12 deficiency (can cause megaloblastic anaemia)
Recent ear surgery
Hypersensitivity to N2O
Any condition where air is trapped within a cavity and expansion may be dangerous (e.g. occluded middle ear, cysts, gross abdominal distension, maxillofacial injuries)
Use >24h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Preconception management

A

(full history of woman and partner if possible - optimise any medical conditions)
Imms: MMR, VZV, HBV

Weight: reduce obesity BMI <30 ideal

Nutrition: ?vegan/vego, assess and manage for nutritional deficiencies (B12, iron, VitD)
Avoid excess caffeine (3-4 cup/day)

CARD: cease all prior to conception. Aim for paternal smoking cessation pre-conception also

Travel: avoid to areas particularly affected by Zika. mosquito and sexual protection if cannot avoid.

Supplements:
- Folic acid from 1/12 prior. 400mcg/day if low risk, 5mg/day if high risk (NTD hx, DM, AEDs, BMI >35, haemolytic anaemia)
- Vit D if high risk group
- B12 6mcg/day if vego/vegan or bariatric surgery
- Calcium 1200mg/day if low dietary intake
Iodine 150microg/day
- iron if deficient, vego/vegan

Genetic counselling:
If high risk refer to geneticist, iff low risk, offer carrier screening e.g. Eugene (out of pocket currently)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Folic acid supplement dose in pregnancy/pre-conception

A
400 microg/day if low risk
5mg/day if high risk:
- DM
- personal or FHx of NTD
- BMI >35
- AEDs
- multiple pregnancy
- haemolytic anaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Vitamin B12 in pregnancy

A

6mcg/day if vegetarian/vegan/bariatric surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

Immunisations to consider pre-conception

A

MMR
VZV
HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Risks of smoking in pregnancy

A

Pre-conception:

  • delayed conception by 2 months
  • 60% increased risk of female infertility
  • male infertility

Obstetric:

  • Miscarriage
  • Preterm labour (2x)
  • placenta praevia (2x)
  • placental abruption (1.5x)
  • stillbirth (3x)
  • Ectopic (2.5x)
  • PPROM (2x)

Fetal:

  • low birth weight (<2500g) (2x)
  • SGA (3x)
  • Birth defects (limbs, clubfoot, cleft palate, eye defects, GI defects)

Postpartum:
- less breastmilk production

Child/adult:

  • SIDS (2.5x)
  • Behavioural issues (ADHD, CD, antisocial)
  • Respiratory disease (asthma, recurrent infection, reduced lung function)
  • Cognition (reduced academic performance)
  • T2DM
  • Obesity
  • HTN
  • Dyslipidaemia
  • Pyschiatric disorders early adulthood
  • Nicotine deopendence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Management of smoking in pregnancy

A
  1. Counselling and QuitLine referral
  2. NRT (1st line is intermittent short acting forms, if patches required make sure are removed at bedtime 16h patches)

Champix and Bupropion not evidenced to be safe or effective in pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Risks of heroin use during pregnancy

A
IUGR
Pre-term labour
Placental abruption
intrauterine passage of meconium
Neonatal abstinence syndrome
Foetal and neonatal death

Other associations:

  • inadequate antenatal care
  • poor nutrition
  • BBV exposure
  • overdose
  • financial hardship
  • unstable accommodation
  • pyschological instability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

Opioid substitution therapy in pregnancy

A

Methadone and buprenorphine both cross the placenta

Methadone has been used for longer, more experience with it. >50% of exposed neonates will show signs of NAS

Buprenorphine - only the mono therapy (without naloxone) is offered to pregnant women. Evidence suggests associated with fewer neonatal complications than methadone (less frequency, less severe NAS and less medication and admission durations)

Concentrations in breastmilk are low, breastfeeding should be encouraged while on OST if no other contraindications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

Features of neonatal abstinence syndrome

A

Develops within first 48-72 hours of birth

  • lasts from 1-several weeks depending on type of opioid use
  • difficulty feeding
  • central and autonomic hyperactivity
  • poor suckling
  • irritability
  • hyperactivity
  • sleep disturbances
  • high-pitched cry
  • seizures (in 5%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Management of neonatal abstinence syndrome

A
Close monitoring in special care nursery for prolonged period
Observation with standardised NAS scoring
Oral morphine (dose and duration based on NAS scoring)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

Complications of alcohol in pregnancy

A
Miscarriage
Stillbirth
Low birth weight
Premature birth
Brain damage
Birth defects
Foetal alcohol spectrum disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

Common impact on child(and then adult) from alcohol used in pregnancy

A
Hyperactivity/inattention/impulsivity
Aggression
Impaired social interactions
Antisocial personality traits
Disrupted schooling
Substance use disorders
Mental health issues
Employment/financial/independent living issues
Criminal system contact
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

Advice for alcohol and breastfeeding

A

Safest not to use alcohol at all while breastfeeding
Definitely no alcohol in first month postpartum and until BF established
If chooses to drink after than, limit consumption as much as possible
Avoid drinking immediately prior to breastfeeding
Option to express prior to alcohol consumption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

Diagnostic features of foetal alcohol syndrome

A
  1. evidence of prenatal alcohol exposure
  2. Growth deficiency (pre or post natal <10th centile)
  3. Facial features (** = sentinel)
    - epicanthal folds
    - flat nasal bridge
    - short palpebral fissures**
    - upturned nose
    - smooth/flat philtrum**
    - thin upper lip **
  4. Neurological dysfunction
    - Structural:
    - -HC <10%
    - -structural brain abnormality on imaging
    - Neurological
    - -any neurological issues NOT due to postnatal event
    - Functional
    - -performance below expected for age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

Foods to recommend avoiding during pregnancy

A

Risk of listeriosis:
- pre-prepared salad vegies (e.g. salad bars)
- raw, undercooked, chilled pre-cooked meats, pate and meat spreads
- unpasteurised dairy, soft, semi-soft and surface-ripened cheeses
Risk of salmonella
- raw eggs/foods containing raw eggs
Risk of mercury
- shark/flake, marlin, broadbill/swordfish, catfish
Risk of hepatitis A
- frozen berries
- bean sprouts
Foods containing saturated fats, added salts and sugars

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Recommended maximum daily caffeine intake per day during pregnancy

A

300g (3-6 cups coffee/tea per day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Recommended water intake during pregnancy

A

750-1000mL above daily pre-pregnancy needs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Vitamin supplements that can be associated with harm if taken antenatally

A
Vitamin C (preterm birth, perinatal death, PPROM)
Vitamin E (PPROM)
Vitamin A (congenital malformation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Physical activity advice in pregnancy

A
  • Specifically designed programs can prevent pelvic girdle pain and reduce severity of back pain
  • Yoga associated with less stress, enhanced relationships, reduced back pain and less reported pain in labour
  • can prevent urinary incontinence
  • low-moderate intensity exercise is safe throughout pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

Impacts of pregnancy on oral health

A

Reduced immune system (increased risk of periodontal infections)
Vomiting/reflux in pregnancy increases acidity -> enamel damage -> decay
Frequent snacks/soft drinks and other cravings (often sweet) can increase risk of tooth decay

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

Recommendations to reduce impact of pregnancy induced vomiting on oral health:

A

Rinse mouth with bicarb soda after vomiting
Avoid tooth brushing directly after vomiting
Use fluoridated mouthwash and toothpaste
Small protein-rich non-cariogenic foods throughout the day
Chew sugar-free gum (esp ones containing xylitol or CPP-ACP) after meals/sugar/acidic drinks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

Women in whom you should screen for haemoglobinopathies (pre-natal or antenatally)

A
  • family history of anaemia or haemoglobinopathy
  • MCV <80 OR MCH <27
    Following ethnic backgrounds:
  • Southern European
  • African
  • Middle Eastern
  • Chinese
  • Indian subcontinent
  • Central and SE asian
  • Pacific Islander/Maori
  • South American
  • Caribbean
  • Northern WA/NT ATSI communities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

What to include in a haemoglobinopathy screen

A

FBE (for MCV+MCH)
Ferritin (exclude Fe def)
Hb electrophoresis

DNA testing if indicated (microcytosis with normal iron and Hb electrophoresis and risk of disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

Hb electrophoresis results in beta-thalassaemia

A

High HbA2 (>3.5%)

Normal HbA2 with low MCV and normal ferritin may be alpha thalassaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

Diagnosing alpha-thalassaemia

A

Requires DNA analysis for definitive diagnosis. Suggested with low MCV and normal Hb eletrophoresis + ferritin level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

Hormones involved in the onset of labour

A

Progesterone

  • suppresses uterine contractility
  • systemic or functional withdrawal (due to reduced responsiveness due to inc. PR-A:PR-B intrauterine expression) leads to increased uterotonin production

Prostaglandins:

  • stimulate contractions, cervical softening and rupture of membranes
  • synthesis is catalysed by COX-2
  • increase the intrauterine PR-A:PR-B ratio-> feed forward mechanism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

Benefits of water immersion in labour

A
  • more tolerable labour pains
  • lower use of pharmacological analgesia
  • lower augmentation rates
  • lower bleeding, reduced risk of PPH
  • shorter labour
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
109
Q

Definition of the puerperium

A

the 6 weeks following delivery during which woman’s physiology returns to pre-pregnancy state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
110
Q

Expected course on uterine involution postpartum

A

Fundus at level of umbilicus immediately post delivery
By day 5-7 halfway between umbilicus and pubic symphysis
By 2 weeks not palpable
By 6 weeks almost back to pre-pregnancy state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
111
Q

Cause of involution and lochia

A

Contractions and reduction of size of myometrial muscle (Cause of after pains)
Thrombosis and hyalinisation of blood vessels -> decidual shedding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
112
Q

Normal progress of lochia

A

Until day 5-6: lochia rubra
Until day 10-12: lochia serosa (darker brown)
Then becomes lochia alba (yellowish/white)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
113
Q

Timing of return of ovarian function post partum

A

In non-lactating women usually by 10 weeks, can be as early as 4-6 weeks

In lactating women highly variable

Make sure to offer contraception from 4 weeks if sexually active

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
114
Q

Healing time of perineal injury

A

Most 1st/2nd and episiotomies will heal within 3 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
115
Q

Care of perineal injuries

A

Keep dry and clean, clean from front to back
Warm sitz baths
Avoid constipation
Advise to watch for excessive pain/PV discharge or malodourous discharge

Abstinence for 6 weeks, advise may be some discomfort when resumes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
116
Q

When to resume sexual activity postpartum

A

Advise abstinence for 6 weeks if any tears
If no tears, as soon as desired/comfortable

Lactating women can have vaginal atrophy and may require topical oestrogen (after BF established) or lubrication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
117
Q

Diet and exercise recommendations postpartum

A

Regular diet ASAP
Full ambulation ASAP
Abdominal strength exercises after delivery pains have subsided (usually 1 day post NVD, 6 weeks post LSCS) - curl-ups while lying in bed (flexing knees and hips)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
118
Q

Bladder changes postpartum

A

Massive diuresis can occur immediately post-partum due to withdrawal of oxytocin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
119
Q

Cathartics use postpartum

A

Psyllium husk
Docusate or
Bisacodyl

Should be given to all women with OASI injury postpartum, and to other women if BNO day 3 (or if otherwise desired)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
120
Q

Managing breast engorgement postpartum

A

If plans to BF:Hand expression in warm shower or pump between feeds, regular feed schedule, wear comfy nursing bra

If not wanting to BF:
Supportive bra (avoid gravity), avoid nipple stimulation or manual expression, tight binding of breasts (e.g. with tight sports bra), cold packs and analgesia PRN
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
121
Q

Post partum mental health changes

A
Transient depression is common in the first week
- mood swings
- irritability
- anxiety
- poor concentration
- insomnia
- crying spells
Typically only mild and subsides by day 7-10
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
122
Q

When to advise women to see their GP re: ?postpartum depression

A
  • If depressive symptoms last >2 weeks post partum
  • if symptoms interfering with daily life
  • ANY suicidal or homicidal thoughts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
123
Q

Family planning recommendations post partum

A

Obstetric outcomes are improved by delaying conception until 18 months post delivery

MUST delay conception at least 4 weeks post live vaccines

Avoid combined oestrogen/progesterone contraceptives while lactation is being established

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
124
Q

Vulnerable groups who are statistically less likely to breastfeed (thus require more support)

A
Aboriginal and Torres Strait Islander Women
Younger women (especially <20y)
Less educated women
Obese women
Lower socioeconomic status
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
125
Q

Benefits of breastfeeding for the infant

A
  • nutrients in perfect composition, bioavailability and readily absorbable state
  • active and passive immunity
  • improved visual acuity
  • improved psychomotor and cognitive development (higher IQ with longer durations of breastfeeding)

Reduced risks of:

  • malocclusion
  • physiological reflux
  • pyloric stenosis
  • GI infections
  • respiratory illness
  • otitis media
  • urinary tract infections
  • meningitis
  • SIDS
  • NEC (in Prem babies)
  • Atopy (breastfeeding during time of antigen introduction facilitates development of tolerance)
  • Some childhood cancers
  • T1DM/T2DM
  • Coeliac diseae (if breastfeeding at time that gluten is introduced)
  • IBD
  • HTN, dyslipidaemia
  • obesity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
126
Q

Maternal benefits of breastfeeding

A
  • reduced risk of breast Ca
  • reduced risk of ovarian Ca
  • reduced risk of GDM women developing T2DM
  • Promotes uterine involution (less bleeding -> preservation of iron stores)
  • ?maybe helps return to pre-pregnancy weight
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
127
Q

What to discuss around breastfeeding antenatally

A
  • importance of exclusive breastfeeding to 6 months and recommend breastfeeding to at least 12 months for nutritional and protective benefits
  • basic breastfeeding management
  • anticipatory guidance for coping with minor problems
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
128
Q

Factors that delay the initiation of lactation

A
  • stressful delivery (due to reduced oxytocin release)
  • Caesarean delivery
  • Maternal T1DM (can delay lactation by 24h)
  • retained placental fragment (persistent progesterone release)
  • maternal obesity (higher levels of progesterone + attachment issues)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
129
Q

Correct technique for breastfeeding

A
  • Mum upright/semi-reclined with good back/feet/arm support
  • “C-hold” - if nipple erect, support outer area of breast, if flat/inverted should hold well behind areola from the bottom to shapebreast between thumb and index finger
  • Support infant behind shoulders, body flexed around mum, nose at level of nipple
  • Tease infant with underside of areola to encourage wide gape, then quickly bring INFANT to the BREAST
  • should be no clicking or sucking in of infants cheeks, slow even rhythm with deep jaw movements, pauses are normal
  • come off breast spontaneously
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
130
Q

Number of breastfeeds per day

A

8-12 typically

Typically will establish pattern within first week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
131
Q

Absolute contraindications to breastfeeding

A

HIV infection (but discuss with specialist)
Active TB
Breast Ca treatment
Breast syphilis
Brucellosis
Infant metabolic conditions requiring special formula (e.g. galactosaemia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
132
Q

Advice around smoking and breastfeeding

A

Ideally quit smoking during pregnancy and breastfeeding
If unable to quit, reduced as much as possible
COMPLETELY avoid smoking 60 minutes prior to feed (and during feed)
Never smoke in same room as infant
Champix and Zyban are not safe during pregnancy or lactation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
133
Q

Signs to monitor if breastfeeding has established

A
  • Content neonate after feed (though may cluster feed at certain period of each day)
  • time remaining on breast (should never be >60 mins)
  • passing urine at least 1x/day first few days (6+ times/day as volume increases)
  • transitional stools by 24-48h-> breastfed stools by day 3-4
  • appropriate weight gain (averaged over 4 week period)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
134
Q

What is lactogenesis stage I

A

After maturation of alveoli of breasts due to prolactin, progesterone and human placental lactogen -> breast able to secrete small amounts of specific milk components (e.g. lactose)
- complete by mid pregnancy

Milk production is inhibited in late pregnancy by high progesterone levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
135
Q

What is lactogenesis stage II

A

Rapid increase in milk production in the first 30-40h following delivery of placenta (due to progesterone withdrawal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
136
Q

Average breast milk production per day

A

800mL/day AVERAGE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
137
Q

Milk ejection reflex

A

Sucking -> pulse of oxytocin from posterior pituitary -> contraction of myoepithelial cells surrounding alveoli -> milk ejected into ducts and lactiferous sinuses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
138
Q

Symptoms women may get due to milk-ejection reflex

A
  • No symptoms at all
  • tingling/prickling/pins and needles sensation
  • sudden feeling of fullness
  • increase in skin temperature
  • feeling of wellbeing/relaxation
  • pain or nausea
  • dripping/leaking from other breast
  • intense thirst
  • uterine contractions + gush of lochia
  • slow sucking of infant (approx 1/sec)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
139
Q

Recommended nutrition for lactating women

A
  • overall increased energy requirements
  • intake affects micronutrient composition of breastmilk only

Vitamin D and iodine (150 microg/day supplementary) is recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
140
Q

Advice to give vegan mothers who choose to raise infant on vegan diet

A

Breastfeed as long as possible (ideally 2+ years)
If not, then soy-based formula for the first 2 years AND dietary advice

Likely will require supplements especially for iron and B12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
141
Q

Schedule of solids introduction in infants

A

From AROUND 6 months (4-6mo depending on infant signs)

First introduce IRON-RICH foods (iron-enriched cereals, pureed meat/poultry/fish, cooked tofu and legumes)

6-8 mo: purees -> mashed -> minced -> chopped foods
Ensure lumpy foods <9mo
8mo: finger foods
12mo: same foods as rest of family, continue iron-rich foods, small frequent servings of nutrient-dense foods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
142
Q

Recommended drinks to offer infants/children

A

NOTHING other than breastmilk/formula first 6 months

Cows milk: only with cereals etc <12mo, >24mo max of 500mL/day
Water (after 12mo)

Fruit juice, soft drinks, cordial should be avoided
Tea, coffee, caffeinated drinks are unsuitable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
143
Q

Foods to avoid in infancy

A

Honey - do not give <12months due to risk of botulism
Animal milks
- FSCM ONLY with cereals/custards etc. in first 12 months
- goat’s milk NEVER GIVE TO A CHILD
- unpasteurised milk NEVER GIVE
- plant based milks (only acceptable is soy follow-on formula)
- nutrient poor, high fat/salt/suagr foods (e.g cakes, biscuits, chips, lollies etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
144
Q

Definition of subgaleal haemorrhage

A

Bleeding into the space between the epicranial aponeurosis and the periosteum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
145
Q

Cause of subgaleal haemorrhage

A

Rupture of emissary veins (which connect dural sinusess to scalp veins)

Most commonly after vacuum delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
146
Q

Potential consequence of subgaleal haemorrhage

A

Life threatening haemorrhage
- up to 250mL (50-75% of neonatal blood volume) can bleed into subgaleal space, with only a 1cm increase in scalp thickness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
147
Q

Mortality associated with subgaleal haemorrhage

A

12-25% in infants admitted to NICU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
148
Q

Risk factors for subgaleal haemorrhage

A
  • Instrumental delivery (esp vacuum)
  • nulliparous
  • 5 min apgar 7 or less
  • cup marks on sagittal suture
  • leadingedge of cup <3cm from anterior fontanelle
  • failed vacuum extraction (requiring forceps/LSCS)
  • high number of pulls/cup detachments/prolonged time from cup attachment to delivery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
149
Q

Clinical features of subgaleal haemorrhage

A

Insidious onset

Localised signs:

  • vague generalised scalp swelling
  • laxity of scalp - then becomes fluctuant
  • ballotable lesion crossing suture lines
  • pitting oedema over scalp/preauricular/periorbital

Generalised signs:

  • 5 minute apgar 7 or less without asphyxia
  • irritable cry or evidence of pain with handling
  • haemodynamic instability (later sign) (tachycardia, tachypnoea, poor activity, pallor, anaemia, coagulopathy, acidosis, death)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
150
Q

Clinical features of caput succadaneum

A

Can cross suture lines and midline

Size and firmness starts to reduce 1h post delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
151
Q

Clinical features of cephalohaematoma

A

(bleeding between periosteum and underlying skull)
more common after instrumental delivery

Soft, fluctuant, localised swelling with well-defined outline
Does NOT cross suturelines
Canincrease in size over 12-24 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
152
Q

Prevention of subgaleal haematoma

A

Promote neonatal IM vitamin K after instrumental delivery +++

Avoid vacuum when contraindicated

Ensure correct placement of cup, correct traction, and abandonment if too many pulls/detachments/prolonged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
153
Q

Early diagnosis guidelines for subgaleal haematoma

A

Surveillance of different levels for all infants post instrumental delivery

If higher risk (ie lots of pulls/detachments etc, more difficult extraction, incorrect cup placement) should have regular formal observations for 12 h, and cord gas + Hb and platelets at delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
154
Q

Management of possible subgaleal haemorrhage

A

Immediately discuss with neonatologist
Prompt evaluation, resuscitation and supportive treatment
- restore circulating blood volume (IVT, blood products)
- circulatory support
- correct acidosis or coagulopathy
Transfer to NICU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
155
Q

Definition of neonatal hypoglycaemia

A

Low BGL <2.6mmol/L
(note that intervention thresholds may differ according to clinical situation e.g. preterm deliveries or at risk babies intervention threshold is lower at 2.0 due to expected drop in BGL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
156
Q

Risk factors for neonatal hypoglycaemia (14)

A
  • nil by mouth
  • preterm birth
  • respiratory distress/TTN
  • LGA/macrosomia
  • IUGR
  • hypoxic-ischaemic events
  • systemic conditions e.g. infection
  • hypothermia (<36C)
  • inborn errors of metabolism
  • maternal medications (esp. beta blockers or valproate)
  • hyperinsulinaemia
  • maternal diabetes
  • congenital hyperinsulinaemic hypoglycaemia
  • iatrogenic hypoglycaemia
157
Q

Reasons- to check BGL in an infant not considered “at risk”

A
  • disinterest in feeding for 8h or more from birth/last feed
  • hypothermia <36
  • jitteriness
158
Q

Recommendations for neonatal hypoglycaemia screening

A

Screen all at risk neonates at 1 and 4h (SA PPG)

159
Q

Symptoms of neonatal hypoglycaemia

A

Mild- moderate:
Neuro: irritability, jitters, tremors, hypotonia, lethargy, temperature instability, high-pitched cry

Respiratory: tachypnoea

CVS:
tachycardia, diaphoresis

Gastrointestinal: poor-feeding, vomiting

SEVERE:
Neuro: eye roll, seizures, altered conscious state

Resp: hypoventilation, apnoea, cyanosis

CVS: pallor

160
Q

Investigations to consider in neonatal hypoglycaemia

A
Serum glucose
insulin
Growth hormone
Cortisol
Ketone level (via UA or glucometer)
161
Q

Basic nursing management of neonatal hypoglycaemia

A

Check temp and manage as indicated
Offer breastfeed/EBM or formula as soon as practical
Alert medical team
Recheck BGL in 30-60 min

162
Q

Management of neonatal hypoglycaemia

A

BGL 1.5-2.5 (or 2.0):

  • offer feed
  • consider 10% glucose infusion at 60mL/day esp if respriatory distress
  • repeat in 30-60 min aiming for >2.5 if enteral or >3.5 in IV replacement

<1.5 at any time (or baby with major illness <2.5)
URGENT MANAGEMENT REQUIRED
- IV 10% glucose bolus 2ml/kg + infusion 90mL/day
- IM glucagon if IV access delayed
- repeat BGL in 30 min
- Aim for >3.5mmol by 30-60 min
Advice from paediatric team

163
Q

Risk factors for neonatal jaundice

A

Set up for haemolysis
- previous child with antibody mediated HDN
- FHx G6PD deficiency or inherited red cell membrane/metabolic defects (hereditary spherocytosis, PKD etc.)
- +ve maternal blood group antibody screen and +ve cord DAT to antibodies associated with HDN
- visible jaundice of any degree within first 24h
Weight loss >10%/poor feeding
Gestation 35-38 weeks

Unwell infant
OR
Confirmed/likely haemolysis
- in utero haemolysis on basis of fetal anaemia + pos maternal antibody screen
- rate of rise of SBR >5 without PTx or continued rise despite PTx
- baby with bilirubin above exchange level

164
Q

Maternal blood group antibodies associated with haemolytic diseaese of the newborn

A

Anti-D
Anti-C
Anti-kell

Others including Anti-A or -B are less likely to cause haemolysis

165
Q

Recommended monitoring for neonatal jaundice

A

Daily clinical assessment for low risk babies prior to discharge
- blanching of skin with finger tip in appropriate light
OR
- transcutaneous POC light reflectance meter
higher risk babies requireblood bilirubin measurements

166
Q

Clinical assessment of neonatal jaundice

A

Extending below nipple line has high sensitivity for plasma levels >75th centile
- therefore should be checked with bilimeter and/or SBR

Clinical assessment is limited in dark skinned babies, therefore should be checked with bilimeter or blood level

167
Q

Bilimeter use and efficacy

A

Unaffected by gestation, postnatal age or skin pigmentation

Underestimates total bilirubin level, especially at higher blood levels
- therefore blood bilirubin should be checked if bilimeter result >75th%ile

168
Q

Use of hour-specific bilirubin charts in neonates

A

Only validated in well babies without haemolysis

Therefore should only be used in well babies >38 weeks chart, and well babies 35-37+6 weeks

169
Q

Indications of exchange transfusion

A
  1. Rising bilirubin despite intensive PTx, approaching exchange line
  2. anaemia with Hb <100, cardiac failure, or hydrops
  3. Suspected kernicterus regardless of bilirubin level
170
Q

Definition of prolonged neonatal jaundice

A

> 2 weeks in >35/40 gestation
OR
3 weeks in <35/40 gestation

Requires investigation, advise parents to present for medical review if any visible jaundice after 2 weeks, or if pale stools at any time

171
Q

Standard investigations for prolonged neonatal jaundice

A
  1. Review NNST results
  2. Total and conjugated bilirubin
  3. Free T4
  4. Urine culture

If above all normal and healthy breast fed baby, reassure that breast milk jaundice, and will resolve over 2-3 months

172
Q

Follow up of jaundiced babies

A

HEARING: AABR for neonatal screening rather than usual test if:
- jaundice due to haemolytic disease
- bili >350 in term baby
- bili >250 in sick term, of a preterm >32/40
- all babies <32/40 or 1500g BW
Should be performed as close to discharge from hospital as possible. If passes, no routine audiology f/up required

ANAEMIA:

  • if confirmed haemolysis, close f/up over 4-6 weeks to watch for late anaemia
  • Most likely with Rh isoimmunisation - weekly CBE and reticulocyte
  • folic acid supp where continued haemolysis suspected
  • if unusual haemolysis, haem advice

ENCEPHALOPATHY
- if any symptoms/signs or who have been unwell with jaundice require long-term follow-up with paediatrician

173
Q

10 significant viral infections in pregnancy:

A
  1. CMV
  2. Parvovirus
  3. Rubella
  4. Measles
  5. Mumps
  6. Varicella
  7. HIV
  8. Hepatitis A
  9. Hepatitis B
  10. Hepatitis C
174
Q

Most common manifestations of congenital cytomegalovirus infection

A
Deafness
Mental disability
Hepatitis
Pneumonitis
Blindness
175
Q

Transmission of cytomegalovirus

A

Transmitted through infectedblood, saliva, urine, breastmilk or through vertical transmission (in utero or intrapartum) or sexual contact

176
Q

Risk of CMV infection in pregnancy transmitting to neonate

A

In primary infection - 50%

In reactivated disease: only 1% transmission rate

177
Q

Features associated with symptomatic fetal infection (11)

A
Microcephaly
Ascites
Hydrops fetalis
Oligo or polyhydraminos
Hepatomegaly
Pseudomeconium ileus
hydrocephalus
IUGR
pleural or pericardial effusion
Intracranial calcification
Abdominal calcification
178
Q

Rate of symptomatic congenital CMV in babies to mothers who develop infection in pregnancy

A

50% transmission in PRIMARY infection
- 10% of infants will be born symptomatic

90% of these infants will develop sequelae
(10-30% mortality rate, 18% hearing loss, neurological conditions - microcephaly, intellectual impairment, seizures, chorioretinitis)

179
Q

Diagnosis of CMV in pregnancy

A

Maternal: CMV serology and repeat 2-4 weeks (if IgG -ve to positive OR rising then primary infection)

180
Q

Management of CMV in pregnancy

A

Supportive management of mother
Check for fetal infection (amniocentesis for PCR/viral culture and serial USS)
Counsel mother re: option to continue pregnancy v terminate
Counsel re: risk of congenital CMV up to 4y following seroconversion (1% risk in 4th year)

181
Q

Management of newborn with known congenital syphilis

A

Paeds at delivery for detailed examination

Test:

  • ophthal examination
  • cranial USS ?hydrocephaly
  • CT brain - intracranial calcification, verntriculomegaly, cerebral atrophy

Labs <3weeks:

  • CMV IgM serology
  • PCR for viral detection +/- viral culture (blood, urine, NPA)

Consider ID input ?antivirals
Paeds review every 3-6 months if asymptomatic, likely more if symptomatic depending on presentation

182
Q

Main pathophysiology behind congenital CMV

A

Fetal infection causes cytolysis leading to areas of focal necrosis and healing by fibrosis and calcification

183
Q

Transmission of parvovirus

A

Direct contact with respiratory secretions and hand-mouth contact
Vertical transmission

Most infectious from 1 week after exposure to before rash onset (likely not infectious after that)

184
Q

Clinical features of parvovirus

A

30-40% subclinica
Fever, myalgias and malaise which settle prior to rash onset (slapped cheek/reticular macular rash)
Arthralgia or arthritis common adults, can develop few weeks after infeciton

Can cause aplastic crisis in people with thalassaemia or sickle cell anaemia

185
Q

Advice to pregnant women to avoid parvovirus

A

Standard precautions
Susceptible pregnant HCW avoid caring for women with known parvovirus
Routine screening not recommended

186
Q

Complications of fetal parvovirus infection

A
Spontaenous miscarriage/stillbirth
- 13% risk <20/40
- 0.5% risk >20/40
Hydrops fetalis 
- 3% risk if maternal infection 9-20/40
- on average 5 weeks after maternal infection

No evidence of congenital anomalies or long term sequelae for infant

187
Q

USS findings of hydrops

A

Ascites
Skin oedema
Pleural and pericardial effusions
Placental oedema

188
Q

Management of pregnant women exposed to parvovirus

A

Check IgG and IgM

  • if IgG positive = immune, no further management
  • if IgG negative monitor in 2-4 weeks ?seroconversion

If infection confirmed, serial USS every 1-2 weeks to assess for hydrops, if any signs, refer to MFM

189
Q

Epidemiology of varicella in pregnancy

A

up to 4% of pregnant women NOT immune
VZV in pregnancy is complicated by pneumonia in 10% of cases
20-30% risk of transmission to neonate

190
Q

Transmission of varicella

A
  • through airborne/respiratory droplets and direct contact with vesicle fluid
  • contagious from 2d before rash until all lesions crusted over (approx 1 week after onset)
191
Q

Risk of foetal varicella syndrome in maternal varicella infection

A

0.5% risk in 1st trimester
1.4% risk in 2nd trimester
Nil in 3rd trimester (but may be at risk of neonatal disease if around time of delivery)

192
Q

Consequences of foetal varicella syndrome

A
Skin scarring
Eye and limb abnormalities
IUGR/LBW
Prematurity
Cortical atrophy, intellectual disability
Decreased sphincter control
Early death
193
Q

Risk of severe neonatal varicella infection secondary to maternal infection

A

If primary CHICKENPOX disease onset in mother >7 days before delivery, neonatal infection is mild (as maternal IgG is protective)

If <7days before or 2 days after, risk of severe infection

No risk if shingles infection - shingles in otherwise healthy pregnancy is not associated with intrauterine infection

194
Q

Definition of significant varicella exposure for pregnant woman

A

Same household as someone with active varicella
Direct face-to-face contact with a person with varicella for at least 5 minutes
Same room for at least 1 hour

195
Q

Prevention of foetal varicella syndrome

A

Preconceptual varicella serology+/- immunisation

If <96h post exposure and seronegative, give zoster immunoglobulin and seek medical care immediately if develop chicken pox

If >96h post exposure consider oral antivirals if >20 weeks, lung disease, immunocompromised or active smoker

196
Q

Management of maternal varicella infection in pregnancy

A

Isolate
If <24h since appearance of rash- oral antivirals

If >24h since onset of rash:

  • no antivirals
  • monitor at home unless underlying lung disease, ISS, or active smoker (in which case monitor in hospital)

Complicated varicella infection (respiratory, haemorrhagic o neurological symptoms, fever >6 days, newpox developing after 6 days) - 7-10 days aciclovir 10mg/kg for 7-10 days (iV then oral)

197
Q

Management of neonates exposed to varicella

A

Maternal chickenpox >7 days before delivery:
No interventions unless <28/40 or <1000g then IV aciclovir

Maternal chickenpox <7 days before to 2 days after delivery:
ZIG 200IU <24h after birth ideally (up to 72h)
no isolation req, still breastfeed

Maternal chicken pox 2-28 days after delivery (or other exposure when mumw as seronegative): Consider ZIG <96h

Maternal shingles - no risk

198
Q

Varicella zoster immunoglobulin doses

A

Neonates: 200iu IM (1x vial)
Adults: 600IU I (3 vials)

199
Q

Risk of vertical transmission of herpes simplex

A

40-50% risk in women with primary infection + active lesions at time of vaginal delivery/ROM
1-3% risk if lesions associated with recurrent infection (thought HSV1 higher at 15%, HSV2 <0.01%)

200
Q

Risk factors for intrapartum neonatal infection with herpes simplex

A

Maternal PRIMARY infection
Multiple lesions
Premature delivery
Premature rupture of membranes

201
Q

Management of HSV in pregnancy

A

If pre-existing:

  • consider suppressive antiviral therapy from 36/40 if multiple recurrent lesions or sooner if frequent symptomatic recurrences
  • careful speculum in early labour to check no active lesions

If first episode in pregnancy:

  • obtain type specific HSV serology and PCR/culture from swab (if both positive for same type then likely recurrent infection)
  • if confirmed new primary <28 weeks, counsel as per pre-gestaional
  • if diagnosis >28/40, consider suppressive therapy from 36 weeks + caesarean delivery regardless of active lesions

If first episode diagnosed during labour:

  • LSCS
  • HSV type specific PCR on genital swab
202
Q

Neonatal management of HSV exposure

A

Asymptomatic low risk neonate (e.g. maternal seroconversion >6 weeks before birth)

  • normal postnatal care
  • at 24h post birth collect surface swabs (eye, throat, umbilicus and rectum) for HSV1/2 PCR
  • collect urine for HSV1/2 PCR
  • observe for signs of infection

Asymptomatic high risk infant (i.e. maternal HSV close to birth or born through active HSV disease and no previous history of genital HSV)

  • paeds at birth, complete exam for signs of HSV
  • neonatal care unit
  • urine for HSV 1/2 PCR
  • CBE (?low PLT)
  • LFT
  • coags
  • HSV PCR on bloods
  • LP
  • commence IV aciclovir
  • surface swabs 24h after birth

Symptomatic infant

  • Above tests
  • IV aciclovir 14-21 days
  • repeat LP after 7h if initially negative with signs of CNS disease
  • repeat LP near end of treatment completion to confirm clearance
203
Q

Clinical signs of neonatal HSV (9)

A

Vesicular skin lesions, atypical pustular or bullous lesions (especially on presenting part)

  • ulcers involving buccal mucosa
  • corneal ulcer, conjunctivitis, keratitis
  • seizures
  • unexplained fever or sepsis with negative blood cultures, not responding to antibiotics
  • low PLT
  • elevated LFTs
  • DIC
  • respiratory distress 24h after birth
204
Q

Clinical features of rubella infection

A

Asymptomatic in 25-50%
May have:
- low grade fever
- transient erythematous rash - cephalocaudal spread with caudocephalic resolution within 3 days
- arthritis and arthralgia (most commonly in women of child-bearing age)
- neuro disorders, thrombocytopaenia (rare)

205
Q

Infectious period of rubella

A

1 week before until 4 days after onset of rash

206
Q

Incubation period of rubella

A

14-23 days

207
Q

Potential (general) outcomes of a maternal rubella infection

A
No effect on fetus
Placental infection only
Placental/fetal asymptomatic infection, but can affect organs
IUFD/miscarriage
Congenital rubella syndrome
208
Q

Risk of congenital rubella complications by gestation

A
  • 90% of fetuses <8 weeks will be affected
  • 50-80% fetuses 8-12 weeks will be infected, half of these will have fetal defects
  • 12-16 weeks 30% fetuses infected, 10%overall risk of fetal defect (sensorineural deafness most likely)
  • > 16 weeks fetal manifestations rare

Maternal reinfection in immune women very low risk of fetal damage

209
Q

Potential features of congenital rubella syndrome

A

Sensorineural deafness
CNS dysfunction (intellectual impairment, developmental delay, microcephaly)
Eye abnormalities (cataracts, retinopathy, glaucoma, strabismus, micropthalmos)
Cardaic abnormalities (PDA, PA stenosis)
IUGR, short stature
Inflammatory lesions of brain, liver, lungs and bone marrow

210
Q

Women who require post natal MMR vaccination

A

Anyone with Rubella IgG <10
OR
10-20 if born in Australia or the Western world

Should receive a second dose of MMR 4 weeks after the first

**ensure to inform NOT to get pregnant within 28 days of vaccination

211
Q

Diagnosis of maternal rubella

A

Test rubella specific IgG and IgM for any pregnany woman with contact with OR clinical features of rubella

If both positive - possible recent infection, repeat test to confirm (4-fold increase in IgG titre is indicative of recent infection)

If both negative

  • susceptible
  • repeat serology if <3 weeks since contact or <7 days since onset of illness
  • if no seroconversion, requires postnatal immunisation
  • if seroconversion occurs, then consistent with maternal infection

IgG negative, IgM positive

  • possible recent infection
  • repeat - if no IgG seroconversion occurs may be false positive IgM (occurs especially in presence of rheumatoid factor)

IgG positive, IgM negative
- past infection or immunisation

212
Q

Counselling women re: seroconversion that indicates maternal rubella infection

A

Counsel regarding risks relevant to gestation

  • termination should be offered if infection occurs in first trimester
  • consider fetal testing if maternal infection in 2nd trimester (CVS may be appropriate in 1st trimester if couple are uncomfortable about termination based solely on risk of fetal infection)
    i. e. rubella PCR, culture and fetal IgM through CVS, amniocentesis or fetal blood sampling
213
Q

Pre-pregnancy management of woman with HIV

A

Refer to HIV physician, sexual health physician and high risk obstetric consultant for discussion and screening
Ensure CST up to date (within last 12 months)

214
Q

Management of HIV positive woman in pregnancy

A

Routine antenatal bloods+ serology for CMV, VZV, HSV, toxoplasmosis, cryptococcus, candida
- CBE, CD4 count, lymphotcyte subsets
- HIV viral load and resistance testing (unless already known)
- baselineLFT, EUC, amylase, lactate, HLA B5701
Refer to tertiary centre for MDT management with HIV specialist, ID specialist and High risk/MFM obstetrician

215
Q

Intrapartum management of HIV positive woman

A

If SROM, consider augmentation
If PPROM 34-37 weeks, immediate delivery (with antibiotic and steroid cover)
If <34 week PPROM- MDT discussion and planning

If viral load undetectable at or after 36 weeks, can have vaginal delivery without intrapartum zidovudine
If viral load <400 - intrapartum zidovudine and consider LSCS
If viral load >400 intrapartum zidovudine and plan LSCS

216
Q

Factors which increase risk of maternal to child transmission of HIV

A

> 70% occurs in labour

Risk increased by:

  • advanced maternal illness
  • high viral load
  • poor maternal immune status (e.g. low CD4 count)
  • ROM >4h before birth
  • Preterm birth
  • breastfeeding
  • procedures that may damage integrity of natural barriers (e.g. FSE, vigorous suctioning, injections through unwashed skin, invasive testing such as CVS)
217
Q

Tests performed in HIV screening

A

Screening test with ELISA for HIV antibody -if positive, then confirmed with Western Blot (if indeterminate, discuss with reference lab + virologist)

218
Q

Risk of perinatal hepatitis B transmission

A

If mother is HBeAg positive risk is 70-90% of developing HBV infection by 6 months (if does not have HBIG and postpartum Hep B immunisation)
Risk with administering HBIG and Hep B reduces to 5-10%

If acute HBV in 1st or 2nd trimester, risk of transmission to newborn 10%, if in 3rd trimester, risk approx 75%

219
Q

Recommended antenatal screening for hepatitis B

A

HBsAg to ALL pregnant women - positive = infection with Hep B
Can have false negatives though due to mutation in HBsAg therefore all women in HIGH RISK groups should also be screened with HBcAB

220
Q

Further tests recommended if pregnant woman found to be HBsAg or HBcAb positive

A

HBeAg (positivity indicates high infective status)
HBeAb (positivity indicates lower risk of spreading HBV infection)
HBcAb
LFTs (and repeat at 28 weeks)
CBE
HBV viral load (repeat before 32 week gestation)

221
Q

Management of HBV in pregnancy

A

Refer to ID specialist and high risk obstetric unit. If high viral loads may be considered from approx 32 weeks (or 28) to reduced risk of perinatal transmission(not indicated if very low viral laod)

222
Q

Postpartum management of neonate born toHBV positive mother

A

HBIG 100 units AND HBV vaccine given within 12 hours - skin should be cleaned prior to injection - continue with normal childhood HBV schedule
Follow up at 8-12 months (2 months post completion of primary schedule) for HBsAg, HBsAb - if antigen positive, refer to paeds gastro or ID
Breastfeeding encouraged

223
Q

Risk of perinatal transmission in HCV RNA positive women

A

approximately 5% - transmission is 3-4 x more likely in event of co-infection with HIV

224
Q

Postpartum management of neonate born to HCV positive mother

A

Clean skin with soap and water if visible blood OR with alcohol wipe prior to injections
HBV vaccination within 12 hours of birth
If co-infection with HBV, also requires 100IU of HBIG
Test for HCV Ab at 18 months of age

225
Q

Risk of fetal transmission and congenital abnormalities of toxoplasmosis

A

Depends on gestation at maternal seroconversion

1st trimester - low risk of vertical transmission (5-15%) but high risk of abnormalities (60-80%)

2nd trimester - moderate risk vertical transmission (25-40%), low risk of congenital abnormalities (15-25%)

3rd trimester - 30-75% risk of vertical transmission (higher rates closer to term), 2-10% risk of abnormalities

226
Q

Abnormalities associated with congenital toxoplasmosis (9)

A
  • Chorioretinitis/retinal scarring
  • Hydrocephalus
  • Intracranial calcification
  • Mental retardation
  • Hepatosplenomegaly
  • Pneumonia
  • Thrombocytopaenia
  • Lymphadenopathy
  • Myocarditis
227
Q

Clinical features of toxoplasmosis

A
Most patients will be completely asymptomatic
Potential symptoms in mild illness: 
- flu-like symptoms
- malaise
- myalgias
- Swollen lymph glands
Severe disease (more likely in immunocompormised)
- ocular toxoplasmosis (blurred vision, photophobia, red eye, tearing)
228
Q

Diagnosis of toxoplasmosis

A

Consider testing toxoplasmosis serology in pregnant women with acute symptoms (e.g. malaise, fever, lymphadenopathy)

If IgG and IgM positive indicates POSSIBLE recent infection

  • IgM can remain positive for years
  • IgA, rising AigG and/or low IgG avidity are more specific for recent infection
  • if both are positive, repeat serology for IgM, IgA and/or IgG titre and avidity
  • if on repeat, High IgM, positive IgA and low IgG avidity consistent with recent toxoplasmos infection
229
Q

transmission of toxoplasmosis

A

Faecal-oral route

  • undercooked, contaminated meat (esp. pork, lamb or venison) or shellfish
  • contaminated water
  • accidental ingestion through contact with cat faeces (e.g. cleaning cat’s litterbox, touching or ingesting anything that has come into contact with cat faeces, accidentally ingesting contaminated soil)
230
Q

Management of toxoplasmosis in pregnancy

A

Further investigations to determine risk to fetus:
- USS to detect abnormalities
- amniocentesis for PCR/culture at 18-20 weeks or >4 weeks after maternal infection
If both above are negative, consider pharmacological treatment if maternal infection is fairly certain

In 1st trimester: counsel woman/partner re: termination if amniocentesis PCR is positive

2nd trimester: Counsel re: termination if USS abnormal
Spiramycin, atavaquone or azithromycin if medication indicated (unknown efficacy)

3rd trimester (as above medical treatment, termination not advised)

231
Q

Intra-/Postpartum management of toxoplasmosis in pregnancy

A

Paeds at delivery
Newborn assessment for congenital toxoplasmosis
- ophthal examination and cerebral ultrasound required
- placenta for histo/PCR
- infant whole blood for PCR, serology for specific IgM and/or IgA, persistent IgG
- infant CSF for PCR

Majority of infected babies will be asymptomatic

Manage with spiramycin oral syrup for first 12 months

  • repeat IgG at 6 months
  • regular paeds/ID review
232
Q

Presentation of listeriosis in pregnancy

A

*always obtain a dietary history from pregnant women with febrile, flu-like ilness, myalgia, headache or diarrhoea

Often asymptmatic
Can mimic pyelonephritis due to loin pain

233
Q

Risks of listeria in pregnanct

A

In early pregnancy: fetal infection can cause miscarriage

In 2nd and 3rd trimesters, if untreated maternal infection, associated with 40-50% fetal mortality (septicaemia, multi end organ damage, still birth, neonatal death)

Neonatal infection: pneumonia, sepsis or meningitis
Mortality rate 3-50%

234
Q

Management of maternal listeriosis infection in pregnancy

A

Mild: PO amoxicillin

Severe: IV amoxicillin + gentamicin

(if penicillin allergy, consider bactrim PO or IV if >12/40)

235
Q

Presentation of neonatal listeriosis

A

Variable, but most commonly:

  • respiratory distress
  • rash
  • fever
  • jaundice
  • lethargy

Suspicious findings include:

  • placental, cord, or post-pharyngeal granulomas
  • multiple small skin granulomas, papular or pustular skin rash
  • Meconium stained liquor <34 weeks
  • purulent conjunctivitis
236
Q

Pathophysiology of UTIs in pregnancy

A
  1. Obstructed urinary flow -> stasis -> increased risk of asymptomatic bacteriuria becoming pyelo
  2. Smooth muscle relaxation secondary progesterone -> reduced bladder and ureteral tone, dilatation of renal pelvices and ureters -> increased bladder volume, urinary stasis, residual volume and VUR
  3. pregnancy-induced changes in urine pH, osmolality, glycosuria and aminoaciduria may facilitate bacterial growth
237
Q

Asymptomatic bacteriuria in pregnancy statistics

A

occurs in 5-10% of pregnancies
30% will develop acute pyelonephritis if untreated
Associated with preterm birth, LBW
Antibiotics associated with reduced preterm delivery and LBW infants

238
Q

Pathogens involved in asymptomatic bacteriuria in pregnancy

A

E coli >80%

second most common is staphylococcus saprophyticus

239
Q

Indications for antenatal MSSU

A

Routine MSSU at booking
Repeat after contaminated specimen
History of recurrent infections outside of pregnancy
Structural abnormality of the urinary tract

240
Q

Gestation of highest risk of UTI in pregnancy

A

Risk begins at 6/40 and peaks 22-24/40

241
Q

Risk factors for UTI in pregnancy

A
Low SES
Sickle cell trait
DM
Neurogenic bladder retention
History of previous UTIs
Structural abnormality of urinary tract
Renal stones
242
Q

Diagnosis of asymptomatic bacteriuria/UTI in pregnancy

A

> 100,000 bacteria/mL

  • <20 white cells (in AB)
  • if 2+ organisms usually contamination and should be repeated

+ clinical findings in acute cystitis

243
Q

General considerations for management of acute cystitis or asymptomatic bacteriuria in pregnancy

A
  • 5 day course antibiotics (10-14 days for pyelo)
  • at least 48h IV if bacteraemia
  • increase fluid intake +/- IVT
  • monitor urine output
  • urinary alkalinisers are safe, but DO NOT USE WITH NITROFURANTOIN (will reduce efficacy)
  • only commence antibiotics for asymptomatic bacteriuria AFTER culture and sensitivities (not empirical based on UA)
244
Q

Antibiotics for uncomplicated UTI (empirical) in pregnancy

A

Cephalexin 500mg BD for 5 days
OR
Nitrofurantoin 100mgBD for 5 days

OR
Augmentin DF BD for 5 days (only if <20/40)
OR
Trimethoprim 300mg daily for 5 days (only if>12/40)

245
Q

Antibiotic options for asymptomatic E coli bacteriuria

A
  1. cephalexin 500mg BD 5 days
  2. nitrofurantoin 100mg BD 5 days (but don’t use Ural)
  3. trimethoprim 300mg daily for 5 days
  4. ADF BD for 5 days
246
Q

Augmentin duo forte use in pregnancy

A

Only use if <20 weeks
Associated with increased risk of necrotising enterocolitis, functional impairment and cerebral palsy, therefore only use inf no alternative

247
Q

Antibiotics options for staph saprophyticus asymptomatic bacteriuria in pregnancy

A
  1. Cephalexin 500mg BD 5 days
    OR
  2. Amoxicillin 500mg TDS for 5 days
248
Q

Antibiotics for pseudomonas asymptomatic bacteriuria in pregnancy

A

Norfloxacin 400mg BD 5 days

Repeat MSSU 48h after treatment completed

249
Q

Management of GBS asymptomatic bacteriuria in pregnancy

A
Penicillin V 500mg BD 5 days
OR
cephalexin 500mg BD 5 days
OR
clindamycin 450mg TDS 5 days

(dependent on allergies)
THESE WOMEN NEED GBS PROPHYLAXIS IN LABOUR

250
Q

Management of acute pyelonephritis in pregnancy

A

48h minimum IV antibiotics
IVT+ monitor urine output
Antipyretics PRN
Monitor for preterm labour

Amoxicillin 2g 6 hourly IV+ gentamicin 5mg/kg daily
OR
ceftriaxone 1g IV daily

Step down to oral antibiotics after >24h apyrexia, clinically improving. Base on susceptibilities.
(doses same as for UTI except cephalexin 500mg QID) and continue for 10 days

251
Q

Indications for antibiotic prophylaxis for UTIs in pregnancy

A

2+ documented separate episodes of CYSTITIS (not asymptomatic bacteriuria)
OR
Single episode pyelonephritis

252
Q

UTI prophylaxis options in pregnancy

A

Nitrofurantoin 50mg nocte (be careful using close to term)
OR
cephalexin 250mg nocte
OR
trimethoprim 150mg nocte (avoid 1st trimester or in women concerned about folate)

253
Q

Indications for tuberculosis screening in pregnancy

A

HIV positive mothers
OR
recent contact with infectious TB (e.g. household)

Not otherwise performed as usually treatment would be deferred until 2-3 months postpartum in latent infection

254
Q

Amphetamine effects on pregnancy

A
Amphetamines: 
- cardiac malformations
- ?other malformations such as cleft palate
- IUGR (impaired placental function)
Methamphetamines(ice/speed):
- preterm labour
- placental abruption

MDMA/Ecstasy:
- little evidence of obstetric complications or teratogenicity, but likely confounding effect as multi-drug users

Risk of neonatal abstinence syndrome with all, lower than risk with opioids. 50% will have some withdrawal but only 5% of infants will require treatment

255
Q

Effects of marijuana in pregnancy

A

Crosses the placenta - may cause withdrawal syndrome in neonates of heavy users
Some evidence of association with IUGR

256
Q

Definition of polyhydramnios

A

AFI >20cm (used to be 24cm)

OR Maximal vertical pool >8cm

257
Q

Amniotic fluid production

A

Mostly produced by amniotic membrane covering placenta and cord
>20 weeks also contribution by fetal kidneys

258
Q

Composition of amniotic fluid

A

Same composition as maternal plasma for first half of pregnancy
Then hypotonic compared to fetal and maternal plasma, with more urea and creatinine than plasma

259
Q

Prevalence of polyhydramnios

A

Affects 1% of pregnancies

260
Q

Causes of polyhydramnios

A
  1. Impaired swallowing
    - anencephaly
    - CNS abnormalities
    - myotonic dystrophy
    - oesophageal atresia
    - tetralogy of fallot
  2. Reduced absorption
    - gut atresias
  3. increased production from fetal membranes
    - spina bifida
    - anencephaly
  4. Excessive urination
    - cardiac overload (high output cardiac failure, fetal anaemia)
  5. Increased placental area
    - multiple pregnancy
    - diabetes
    - placental tumour (rare)
261
Q

Complications associated with polyhydramnios

A

Maternal:

  • overdistention -> PROM
  • pain
  • unstable lie
  • cord prolapse
  • abruption
  • PPH

Fetal/neonatal:

  • associated fetal anomalies
  • asphyxia from cord prolapse
  • prematurity
262
Q

Clinical features of polyhydramnios

A
  • SFH large for dates
  • tense abdomen
  • difficulty palpating fetal parts
  • reduced fetal movements
263
Q

Investigations to consider in polyhydramnios

A

USS (to confirm)
- detect fetal structural anomalies

Diagnostic amniocentesis
Exclude treatable causes (fetal anaemia, cardiac failure)

264
Q

Oligohydramnios definition

A

Varies with gestational age, but generally:
AFI <5cm
Deepest pool (MVP) <2cm

265
Q

Causes of oligohydramnios

A

MATERNAL:

  • PROM
  • poor placental diffusion
  • drug effect

FETAL:

  • hypoxia
  • fetal anomalies (renal agenesis, renal dysplasia, urethral valve anomalies)
266
Q

Complications associated with oligohydramnios

A

High risk pregnancy
Fetal anomalies
IUGR
Fetal hypoxia (related to poor placental function)

Early severe oligohydramnios associated with pulmonary hypoplasia and fixed deformities of flexion

267
Q

Risks associated with poor glycaemic control in pregnancy

A
  • congenital malformations
  • pregnancy complications
    (macrosomia, IUGR, preterm birth, PET, shoulder dystocia, IUFD)
  • operative delivery or LSCS
  • Neonatal complications (hypoglycaemia, jaundice, respiratory distress)
268
Q

Hypoglycamic agents safe in pregnancy

A

Metformin
Insulin

All else have limited evidence and should be discontinued prior to pregnancy

269
Q

Pre-conception counselling for pre-existing diabetes

A
  • Discuss risks of poor glycaemic control in pregnancy
  • plan reviews with woman’s GP, endocrinologist/physician, DNE
  • delay attempts of conception until BGL optimised (HbA1c <75, ideally <6.5%
  • change to pregnancy safe hypoglycaemics (metformin, insulin)
  • If T1DM, consider change to continuous subcut pump (refer to diabetes service)
  • folate 5mg daily for 6 weeks prior to conception
270
Q

Antenatal care specific for women with pre-existing diabetes

A
  • refer to high risk clinic + DNE
  • aspiring 100mg nocte
  • weekly DNE monitoringofBGL
  • 2-4 weekly specialist appointments

ADDIT investigations:

  • booking: HbA1c, TFTs, early morning spot urine ACR
  • UA for protein every visit
  • confirm dates with dating scan
  • consider early 16/40 morphology if appropriate
  • If HbA1c >10%, fetal echo at 20-22 weeks
  • Consider growth scans in third trimester

BGL MONITORING:
- change monitoring to include fasting+ 2h post-prandial measurements

REFER:

  • ophthal
  • high risk clinic, obs med, endo, DNE
271
Q

Timing of birth for women with T1DMor T2DM

A

Should always occur <40+6
(but only if BGL within target, normal growth and AFI and otherwise uncomplicated pregnancy)

Induction at 38+6 if: abnormal AFI, difficulty maintaining target BGL at 38/40, macrosomia or IUGR, HTN/PET developing

IF birth likely <37+0, consider steroids for fetal lung maturity, admitfor additional glucose monitoring and increased insulin at direction of obs med/endocrine

272
Q

Method of birth for women with pre-existing diabetes

A

Vaginal birth is safe if EFW <4kg - discuss risks of IOL and potential shoulder dystocia

273
Q

Intrapartum care for women with T1DM

A

CTG
Consul with physician
Avoid prolonged labour and water overload
If ordered, give oxytocin with NORMAL SALINE (not Hartmann’s) to prevent hyponatraemia
Insulin infusion as per protocol, with hourly BGL monitoring

274
Q

Intrapartum care for women with T2DM

A

Continue pre-existing insulin regimen until labour is established, or no later than midnight on day of admission for IOL
Continue metformin until labour established
Hourly BGL (if >8 over 2h period and birth not imminent, to commence insulin infusion)
Continuous CTG
If giving oxytocin, give with normal saline
Beware of risk of shoulder dystocia
Cease dextrose/insulininfusionimmediately after birth

275
Q

Management of neonates born to women with T1/T2DM

A

Paediatrician aware of birth
Feed within 60 minutes (ideally BF)
First BGL <1h of age
Most babies need close observation in nursery for hypoglycaemia, polycythaemia, jaundice, hypocalcaemia, RDS

276
Q

Postpartum care for women with non-gestational diabetes

A

Send placenta for histopath
Review hypoglycaemic therapy early (risk of hypos)
Appropriate contraception
Encourage breastfeeding for minimum 2 months
Ensure appropriate hypoglycaemic agents for breastfeeding

277
Q

Hypoglycaemics safe in breastfeeding

A

Insulin (all forms)
Metformin

Glibenclamide and glipizide (NOT gliclazide or glimeprimide)

NOT SAFE:
- glitazones, acarbose, DDP-4 inhibitors (-gliptins), GLP1 antagonists and SGLT-2 inhibitors

278
Q

Target BGLs in pregnancy

A

Fasting <5
Postprandial (2h) <6.7

If 2 or more of the same reading is elevated in one week, step up in management

279
Q

How to administer OGTT in pregnancy

A
75g glucose load 
Fast from food for at least 8h
Drink glucose over 10-15 minutes
Remain seated and non-smoking for duration of test
Blood at fasting, 1h, and 2h
280
Q

Contraindications to OGTT

A

Gastric bypass surgery

gastric banding usually okay

281
Q

When to perform an early OGTT in pregnancy (8)

A

In women who are at risk for OVERT diabetes in pregnancy (FBG >7 or 2h BGL >11)

  • previous hyperglycaemia (including in pregnancy)
  • maternal age >40y
  • ethnicity: Asian, Indian subcontinent, ATSI, Pacific islander, Maori, Middle eastern, non-white African
  • Family history of DM (1st degree relative with DM OR sister who had GDM)
  • pre-pregnancy or booking BMI >30
  • Previous macrosomic baby (>4.5kg or >90th centile)
  • PCOS
  • Medicated with steroids or antipsychotics
282
Q

Statistics of DVT in pregnancy

A

90& occur in LEFT leg

>70% are iliofemoral (higher risk of embolisation than calf DVT)

283
Q

Management of VTE in pregnancy

A

LMWH 1mg/kg BD
3 months if uncomplicated distal DVT OR 6 months for PE or proximal DVT

If therapy finished before end of pregnancy, prophylactic dose should continue until 6 weeks postpartum

284
Q

Postpartum options for pharmacological treatment or prevention of VTE

A

LMWH - safe in breastfeeding
Warfarin - safe in breastfeeding NOT SAFE IN PREGNANCY

NOACs unsafe in pregnancy AND breastfeeding

285
Q

Management of uncomplicated superficial thrombophlebitis in pregnancy

A

Aspirin 100mg for 5-7 days + TEDS + analgesia

If not resolved, for enoxaparin 40mg for 7-10 days, if not resolved for ultrasound

286
Q

Features which complicate superficial thrombophlebitis in pregnancy (and indicate management with enoxaparin from outset)

A

Previous episodes in current pregnancy
Length >20cm
Previous personal or family history (1st degree) of DVT

287
Q

Incidence of VTE in pregnancy

A
  1. 5-2/1,000 pregnancies affected
    - 25% are PE
    - 1 in 40 PE in pregnancy is fatal
288
Q

Increased risk of VTE in pregnancy and postpartum period

A

5-10 fold increased risk antenatally

Further 15-25-fold increased risk postpartum

289
Q

Factors in assessing women with history of VTE for antenatal prophylaxis

A

If on previous long-term anticoagulation (therapeutic dose LMWH)
2 or more previous VTE (prophylactic or intermediate dose LMWH)
1 previous unprovoked or oestrogen related VTE (prophylactic dose)
1 previous VTE provoked by non-oestrogen transient risk factor (surveillance)

290
Q

Consideration of antenatal VTE prophylaxis in women with family history of VTE

A

If 1st degree relative with VTE NOT in setting of active malignancy - clinical vigilance or prophylactic LMWH if significant clinical risk factors

291
Q

Antenatal VTE prophylaxis for women with known thrombophilias

A

Protein C or S deficiency OR FVL heterozygote: clinical vigilance

FVL homozygotes, prohrombin gene mutation homozygotes, double heterozygote FVL/PGM or antithrombin deficiency: clinical vigilance may be appropriate if no family history of VTE, if family history prophylactic LMWH at least

292
Q

Side effects of long term LMWH

A
Bruising and pain at injection site
Allergic skin reaction (rare)
Thrombocytopaenia (HIT uncommon)
Reversible osteoporosis
Rise in ALT
293
Q

Contraindicationsto LMWH use in pregnancy

A

History of HIT
Actively bleeding
High risk (e.g. placenta praevia)
Delivery expected within 24h
Intracranial haemorrhage or ischaemic stroke within past 4 weeks
Uncontrolled hypertension (SBP>200 or DBP>120)

Precautions:
CrCl <30
PLT <80
Coagulopathy

294
Q

Peripartum LMWH considerations

A

Therapeutic LMWH - no regional analgesia for 24h
Prophylactic LMWH- no regional analgesia for 12h
No LMWH within 4h of spinal or removal of epidural

295
Q

Causes of thrombophilias

A
Inherited:
PROGOACULANT factor abnormalities
- FVL mutation (causes activated protein C resistance)
- prothrombin gene mutation
- plasminogen activator inhibitor

DEFICIENCIES of endogenous proteins in coagulation cascade:

  • Protein C deficiency
  • Protein S deficiency
  • Antithrombin deficiency

ACQUIRED:

  • lupus anticoagulant
  • antiphospholipid antibodies
  • anticardiolipin antibodies

MIXED inherited/acquired:
- hyperhomocystinaemia

296
Q

epidemiology of thrombophilias in pregnancy

A

15% of Western populations are affected with inherited thrombophilia
Inherited disposition can be identified in 60-70% of women presenting with DVT

297
Q

Indications for investigating a woman for thrombophilia

A
  • Strong family history of VTE in 1st and 2nd degree relatives (only check for inherited conditions)
  • recurrent (3+) first trimester miscarriages
  • Second trimester fetal loss
  • any previous history of VTE
  • stillbirth
  • Early onset PET <34 weeks
  • IUGR delivered <34 weeks
298
Q

Investigations to consider in thrombophilia screen

A
Lupus anticoagulant
Protein C and S (Protein S should not be measured in pregnancy)
Activated protein C resistance (APCR)
Factor V leiden
Prothrombin gene
MTHFR
homocysteine
Anticardiolipin antibody
299
Q

Antenatal management of women with thrombophilias

A

Refer to obs med/physician/obstetrician with expertise
Arrange ongoing care in level 2-3 hospital
Antenatal aspirin
Increased feto-placental surveillance antenatally
Consider if LMWH heparin necessary

300
Q

Factor V Leiden statistics

A

Heterozygosity present in 20-40% of non-pregnancy people with VTE
Homozygosity carries 80-fold increased risk for VTE
Occurs in 5-15% of European populations (rare in Asian or African populations)
Risk of VTE in pregnancy for FVL carriers is 0.2% (due to low prevalence in pregnancy overall)

301
Q

Obstetric risks associated with factor v Leiden disease

A
Second and third trimester fetal loss
Severe IUGR
Abruption
Severe early onset PET
Preterm delivery
Increased risk of pathological Doppler measurements
302
Q

how to screen for factor V leiden disease

A

Screen with abnormal phenotype (Activated protein C resistance/APCR)

303
Q

Prevalence of Prothrombin gene mutation

A

2-5% prevalence

More prevalent in Caucasian women

304
Q

Obstetric risks associated with prothrombin gene mutation

A

3-fold increased risk VTE
?PET (controversial association)
IUGR
Placental abruption

305
Q

Which thrombophilia screens are altered in pregnancy

A

Protein S - there is a marked physiological decrease in pregnancy, therefore should not take until at least 8 weeks postpartum

306
Q

Prevalence of protein C and S deficiency

A

PC: 0.3%
PS: 0.1%

307
Q

Obstetric risks associated with protein C and S deficiency

A
VTE 
Stillbirth
Fetal loss (PS deficiency associated with recurrent loss)
PET
Abruption
IUGR
308
Q

Epidemiology of antithrombin deficiency

A

Rarest of inherited thrombophilias but MOST thrombogenic- only thrombophilia that will ALWAYS require thromboprophylaxis in antenatal and postnatal period
Prevalence 1 in 1,000-5,000

309
Q

Definition of antiphospholipid syndrome

A

Autoimmune disorder defined by associated of vascular thrombosis and/or pregnancy morbidity with specified levels of antiphospholipid antibodies (either Lupus anticoagulant or anticardiolipin antibody)

310
Q

Epidemiology of antiphospholipid syndrome

A

Most common acquired thrombophilia in pregnancy
Predominantly affects young women
Prevalence in pregnancy approx 2%

311
Q

Who to screen for antiphospholipid syndrome and how

A

ANF and ACA in women with history of:

  • early onset(<32w) PET and/or IUGR
  • fetal death
  • placental abruption
312
Q

Obstetric risks associated with antiphospholipid syndrome

A
Recurrent early pregnancy loss (<10 weeks)
PET
Thrombosis
Abruption
IUGR
preterm birth
313
Q

Diagnosis of antiphospholipid syndrome

A

Lupus anticoagulant detected on 2 or more occasions at least 6 weeks apart

Anticardiolipin antibodies with moderate-high IgG or or IgM antibodies on 2 occasions at least 6 weeks apart

314
Q

Antenatal management of women with antiphospholipid syndrome

A

Aspirin 100mg/day - if history of late fetal loss or IUGR

  • early dating scan
  • close BP and UA surveillance
  • uterine artery dopplers at 20 and 24 weeks(if abnormal, consider 2-3 weekly scans)
  • 4 weekly scans to assess growth and AFI if uterine arteries normal
  • consider heparin
315
Q

Contributors to hyperhomocystinaemia

A
Deficiencies in Vit B12, folate, B6
GI malabsorption
Renal disease
Thyroid deficiency
Smoking
Coffee and alcohol consumption
316
Q

Risks associated with hyperhomocystinaemia

A
  • early onset PET
  • placental abruption
  • neural tube defects
  • stillbirth
  • IUGR
  • Vascular disease
  • recurrent VTE (if severe)
  • fetal loss
317
Q

most common gene mutation causing hyperhomocystinaemia

A

MTHFR

318
Q

Antenatal management of women with hyperhomocystinaemia

A
Avoidsmoking, alcohol, coffee
Well balanced diet
Folic acid
Early dating scan + 12 weeks scan for neural tube defect
Close PET surveillance
Regular growth and wellbeing ultrasound
319
Q

Prevalence of hyperthyroidism in pregnancy

A

0.2%

95% of these cases are due to Graves’ disease

320
Q

Management of Graves’ disease in pregnancy

A

Refer to endocrinologist + obstetrician
Anti-thyroid therapy (propothiouracil likely as less fetal effects) - on lowest maintenance dose to keep free T4 in high normal range
- check T4 and TSH 6-weekly
- monitor for fetal tachycardia

Propanolol 40mg TDS if symptomatic

321
Q

Obstetric complications of untreated hyperthyroidism

A

Preterm birth
Perinatal mortality
Fetal and neonatal thyrotoxicosis

Risk of thyroid storm triggered by stressof infection, labour, or operative delivery (high risk of maternal and fetal morbidity and mortality)

322
Q

Antenatal management of hypothyroidism

A

Optimise T4 and TSH pre-conceptually

Increase thyroxine by 30% immediately in first trimester (2 extra doses per week)
Check TFT 4 weekly in T2, then 6-8 weekly
Aim for TSH 0.5-2.5

Postpartum, return to pre-pregnancy dose and re-check 6-8 weeks postnatally

323
Q

Timing of prophylacitc anti-D in Rh negative pregnant women

A

28 and 34 weeks

324
Q

Sensitising events which indicate prophylactic anti-D in pregnancy Rhesus negative women

A

First trimester:

  • miscarriage
  • termination of pregnancy
  • ectopic pregnancy
  • Chorionic villus sampling

Second & Third trimester:

  • Amniocentesis/cordocentesis
  • Fetal death
  • Abdominal trauma significant enough to cause fetomaternal haemorrhage
  • Antepartum haemorrhage
  • External cephalic version
325
Q

Antii-D dose

A

Multiple pregnancy: 625IU

Sensitising event <12 weeks: 250IU

Sensitising event >12 weeks (or routine prophylaxis): 625IU

326
Q

How much Rh positive fetal RBCs will anti-D dose neutralise

A

250IU:2.5mL fetal RBC

625IU: 6mL fetal RBC

327
Q

Rationale for routine anti-D prophylaxis

A

Silent transplacental haemorrhages will lead to very small amounts (0.1mL) of fetal RBC accessing maternal circulation, this usually occurs after 28 weeks and especially around time of delivery

328
Q

Management of pregnant women with preformed anti-D antibodies

A

Discuss with MFM specialist
Assess monthly until 28 weeks, then every 2weeks in 3rd trimester
Non-invasive fetal genotyping (cell-free DNA)
If significant rise, maternal anti-D titre >1/16, or history of Rh disease in previous pregnancy fetal monitoring with MCA PSV

329
Q

Requirements of RBCs use in fetal intrauterine transfusion

A
  • O group (or ABO identical with fetus)
  • leucodepleted
  • CMV negative
  • irradiated (to prevent graft v host disease)
  • Plasma reduced
  • <5 days old
  • Rh and Kell negative
  • Indirect antiglobulin test crossmatch compatible with mother’s plasma
330
Q

Physiological changes to the renal system during pregnancy

A

Increased renal blood flow (due to increased cardiac output), increasing GFR by up to 50%

  • fall in serum creatinine, urea, calcium and bicarbonate
  • tubular capacity to resorb glucose and protein is exceeded -> proteinuria + glycosuria

Size of kidney increases due to increased blood flow (R>L due to dextrorotation of uterus)
Dilatation of pelvicalyceal system R>L, up to 15-20mm, due to progesterone activity on relaxing smooth muscle

Increased renin and aldosterone secretion -> sodium and water retention, fall in serum albumin and osmolality

Increased EPO and vit D secretion

331
Q

Diagnostic criteria for GDM

A

OGTT results:
Fasting BGL 5.1-7
1h BGL 10-11
2h BGL 8.5- 11

(any one of these results = diagnosis)

Below this range is normal
Above this range is OVERT diabetes

332
Q

Epidemiology of PROM and PPROM

A

PROM occurs in 10% of all pregnancies

PPROM occurs in 2-3% of pregnancies, but is associated with 40% of preterm deliveries

333
Q

Risk factorsfor PPROM

A
  • Past history of PPROM/preterm delivery
  • urogenital tract infection/colonisation
  • APH
  • cigarette smoking
  • past history of cervical surgery
  • amniocentesis in current pregnancy (PPROM in this setting associated with more favourable outcomes)
  • cervical length <25mm
  • positive fetal fibronectin
  • nutritional deficiencies
  • lean maternal body mass
  • multiple pregnancy
  • polyhydramnios
334
Q

Risks associated with PPROM

A

Maternal:

  • infection (chorio, endometritis, septicaemia)
  • increased risk of operative delivery and associated risks

Fetal:

  • preterm delivery (most deliver within 1 week of PPROM)
  • associated neonatalmorbidities (HMD, IVH, periventricular leukomalacia, neurological sequelae, infection - sepsis, pneumonia, meningitis, NEC, retinopathy)
  • pulmonary hypoplasia
  • MSK/facial deformities
  • malpresentation
  • cord events incl. prolapse
  • placental abruption
  • perinatal mortality
335
Q

Investigations to perform in PPROM

A
HVS MCS
LVS MCS
GBS PCR
\+/- STI screen
MSSU

USS: fetal growth, +/- dopplers,

CRP + CBE daily for 3 days (then twice weekly if expectant management)

If expectant management, weekly HVS MCS

336
Q

Management of PPROM (general principles regardless of gestation)

A

Antibiotics:

  • prophylactic: IV benzylpenicillin 3g loading then 1.2g 4 hourly for 48 hours PLUS PO erythromycin 250mg QID for 10 days
  • if signs of chorio: amox 2g IV 6 hourly, gentamicin 5mg/kg IV daily, metronidazole 500mg IV BD (total 5 days treatment - can change to PO postnatal if afebrile)

Tocolytics;

  • NEVER GIVE if signs of chorio
  • if contractions present but not in established labour, nifedipine can be given to prolong pregnancy for 4h while obtain steroid cover

Corticosteroids
- 11.4mg IM betamethasone in 2 doses 24h apart

Magnesium sulphate:
- if delivery anticipated within 24h, 24-30/40 gestation

Aim to deliver >34/40 if GBS positive OR >36/40 if GBS negative
However if any contraindicationsto expectant management (APH, fetal compromise, signs of chorioamnionitis, established labour), delivery when indicated

337
Q

Surveillance required in expectant management of PPROM

A
  • CTG daily for first 3-6 days then twice per week unless indicated
  • CBE + CRP daily for 3 days then twice weekly
  • HVS swab weekly
338
Q

Statistics of preterm labour

A
  • > 50% of women who present in preterm labour will continue their pregnancy
  • occurs in 5-10% of all deliveries
  • prematurity is the cause for 75% perinatal deaths
339
Q

Risk factors associated with spontaneous preterm labour (12)

A
  • previous preterm birth
  • multiple pregnancy
  • polyhydramnios
  • urogenital tract infection
  • previous cervical surgery
  • uterine anomalies
  • periodontal disease
  • bleeding in 2nd trimester
  • extremes of age
  • smoking
  • low pre-pregnancy weight
  • pregnancies achieved through ART
340
Q

Strategies for prevention of preterm labour

A

No population based interventions, but following may be suitable in at risk women:

  • cervical length assessment at 20/40 (mean is 42mm, intervention considered if <25mm)
  • supplemental progesterone (Cxlength10-20mm)
  • Cervical cerclage (history of cervical incompetence, length <25mm at <24/40)
341
Q

Factors to consider when using fetal fibronectin

A

Should be undetectable from 22-35 weeks (>35 weeks less valuable)

Must use STERILE water as lubricant - as intravaginal lubricants or disinfectants may interfere with antibody reaction and cause false negatives

False positive can occur with blood or semen

342
Q

Management of pre-term labour:

A

Antibiotics- IV benzylpenicillin 3g loading, 1.2g 4hrly (only if active preterm labour, reduces maternal infection rate, no benefit to fetus)

Tocolytics - if need to transfer to another unit/give time to cover with steroids

Corticosteroids: if gestation age 23-34+6 and risk of imminent preterm birth or planned/expected within next 7 days

Mode of Magnesium sulphate: 24-30/40 gestation for neuroprotection where birth is anticipated within 24h

Mode of delivery:
If breech and viable -> caesarean
If cephalic, aim for vaginal
If <26/40 multiple, caesarean

Attendance of paeds/neonatologist at delivery. Dual vessel cord blood gas, sent placenta for histopath + swab

343
Q

Definition of small for gestational age, IUGR, or low birthweight

A

SGA: weight OR abdo circumference <10th percentile for GA
IUGR: Evidence of growth restriction or arrest with EFW or birthweight<10th centile

Low birthweight: <2500g
Very low BW: <1500g
Extremely low BW <1000g

344
Q

Normal growth velocity of the fetus

A

5g/day 14-15/40
10g/day 20/40
30-35g/day 32-34/40

Growth rate decreases >34 weeks

(growth rate lower in multiples than singletons)

345
Q

Factors commonly associated with SGA (not IUGR)

A
Race
Maternal size
Female fetus
Nulliparity
History of baby with SGA
Matrilineal tendency
346
Q

Common factors assocaited with fetal growth restriction

A

MATERNAL:

  • multiple pregnancy
  • smoking, alcohol, amphetamines, cocaine
  • Low SES
  • DV
  • PET
  • previous stillbirth
  • obesity
  • Chronic HTN
  • Connective tissue disorders
  • Thrombophilias
  • diabetes
  • cardiac disorders
  • hypotension (<60mmHg diastolic)
  • respiratory disease e.g. severe asthma
  • anaemia
  • renal disease
  • medications (narcotics, chemo)
  • poor nutrition

FETAL FACTORS:

  • fetal infection
  • malformations
  • chromosomal defects

PLACENTAL FACTORS:

  • abruption
  • praevia
  • placentitis/vasculitis
  • chorioamnionitis
  • Placental cysts
  • decreased uteroplacental blood flow

UTERINE FACTORS:

  • fibroids
  • morphological abnormalities (especially uterine septum)
347
Q

Causes of SGA/IUGR

A

CCPP acronym

Constitutional
Chromosomal
Perinatal infections
Placental insufficiency

348
Q

Aetiology of asymmetric v symmetric IUGR

A

Symmetric (20-30%)

  • all organs decreased proportionally
  • due to impairment of early fetal cellular hyperplasia

Asymmetric (70-80%)

  • Relatively greater decrease in abdominal size (liver and subcut fat) than HC
  • due to fetal adaptation to hostile environment, redistribution of blood flow in favour of vital organs
349
Q

Percentage of SGA babies who are constitutionally small

A

70%

Healthy fetuses with no long term morbidity

350
Q

Risks associated with babies who have IUGR

A
Still birth
Birth hypoxia
Neonatal complications
Impaired neurodevelopment
T2DM and hypertension in long term
351
Q

Chromosomal causes of IUGR

A

(20% of IUGR/SGA)
Usually EARLY and SYMMETRICAL <5th%ile

  • aneuploidy
  • multiple deletions
  • gene mutations
  • placental mosaicism
352
Q

Perinatal infections which can cause IUGR

A

(5% of IUGR due to infection)

  • CMV most common
  • rubella
  • toxoplasmosis
  • varicella
  • syphilis
353
Q

Placental insufficiency causes of IUGR

A

Many causes, often recurrent

e.g. PET, abruption etc. manifestaitions

354
Q

“Other” causes of IUGR

A

Non-genetic congenital abnormalities (2%)
- hypoxaemia (e.g. cyanotic heart disease, severe anaemia)

Multiple gestation

  • nutritional
  • complications e.g. twin-twin, PET

Maternal factors

  • reduced placental blood flow (HTN, DM, collagen disease, lupus, obstetric causes)
  • smoking
  • toxins e.g. warfarin, AEDs
355
Q

Prevention strategies for SGA/IUGR

A
Smoking cessation
Nutritional advice 
- well balanced
- severe dietary restriction associated with LBW
- low fasting BGL associated with LBW
356
Q

Most sensitive measurements for detecting SGA/IUGR

A

AC is most sensitive SINGLE measurement (EFW also good)

Serial RELATIONSHIP between HC and AC, along with AFI interpretation is most useful for identifying growth pattern
- i.e. reduced AC growth with maintained HC growth, associated with oligohydramnios = IUGR

** oligohydramnios without an obvious cause is associated with high perinatal mortality

357
Q

Investigations to perform in a fetus thought to be IUGR

A
Bloods (if early <32/40):
- Hb
- ?thrombocytopaenia
- TORCH screen
If severe early IUGR, consider: 
- thrombophilia screen
- karyotype

USS:

  • AC/HC/AFI
  • UA Doppler surveillance (if increased resistance, repeat in 2 weeks, if absent or reversed diastolic flow, admit and steroid load, usually needs delivery within days)
358
Q

Management of late onset growth restriction (>32 weeks)

A

Usually reflects mild-moderate uteroplacental dysfunction

Serial growth and AFI every 2 weeks

359
Q

Delivery planning for growth restricted fetuses

A

Depends on aetiology, severity and gestation

If moderate:

  • consider IOL if cervix favourable >36/40
  • delay until >37/40 if normal surveillance

If significant:

  • Aim to delivery 34-36 weeks
  • if very preterm, delay until imminent signs of fetal compromise
  • delivery if>34/40 and AREDF
  • If IUGR and oligohydramnios >36 weeks, deliver

**If associated with AREDF, almost always requires LSCS delivery

360
Q

Neonatal recommendations for low birthweight babies on discharge

A

Routine iron supplement for all babies <2500g

- 2mg/kg/day from approx 8 weeks to 12 months of age

361
Q

Procedure for instrumental delivery

A

A: abdo palp (No fetal head palpable), address woman, analgesia, assistants
B: bladder empty
C: cervix check (fully, membranes ruptured)
D: determine position, station and pelvic adequacy
E: equipment- inspect vacuum cup, pump and tubing, check pressure. OR check correct forceps, blades match and lock
F: FLEXION POINT- position cup 3cm anterior to posterior fontanelle and using Finger to clear maternal tissue
FORCEPS: apply blades (left first)
G: Gentle traction
H: HALT - stop vacuum if no progress with 3 pulls, 3 pull offs or no significant progress after 20 minutes
HANDLE ELEVATED: elevate forceps handles in axis of birth canal
I: Incision - consider episiotomy
J: Jaw - remove cup/forceps when jaw is reachable or delivery assured

362
Q

Indications for operative vaginal delivery

A

Maternal:

  • inability to push
  • Prolonged 2nd stage (3h with epidural, 2h without)
  • Cardio or vascular conditions
  • neurological or muscular disease
  • significant vaginal bleeding

Fetal:

  • suspected compromise
  • malposition with relative dystocia (e.g. OP/OT)
363
Q

Contraindications to operative vaginal delivery

A
  • operator inexperience
  • incompletely dilated cervix
  • unknown fetal position
  • unengaged head
  • malpresentation (e.g. face or brow)
  • suspected CPD
  • GA <36/40 (for vacuum only)

(Relative:)

  • fetal predisposition to fracture e.g. OI
  • fetal bleeding disorder (e.g. haemophilia)
  • Maternal bloodborne virus
364
Q

Postpartum care following caesarean

A
  • analgesia
  • early removal of IDC (within 24h)
  • early mobilisation and hydration
  • deep breathing and coughing exercises +/- physio
  • diet as tolerated
  • debrief on birth and impact on future pregnancies
  • observe for postop complications (ileus, UTI, URTI, DVT, wound infection)
365
Q

Criteria for confirmed miscarriage

A
  • evidence of intrauterine fetal pole (CRL) >6mm on TV scan with absent heartbeat
  • Gestation sac >15mm without fetal pole
  • successive scans of gestation sac <15mm fail to show change in size over 10-14 days
  • substantial tissue within uterus >15mm with a history of blood loss and possible passage of tissue (incomplete miscarriage)
  • Small fetal pole seen and bHCG is falling
366
Q

Expectant management of miscarraige

A
  • 70% will resolve spontaneously
  • contents <15mm likely to resolve spontaneously
  • 20% will need subsequent D&C especially if contents >15mm
  • Complete resolution may take weeks
  • less likely to be successful if there is an intact non-viable fetus and gestation sac

Need review 7-10 days after diagnosis, consider repeat ultrasound if there were previously contents noted

367
Q

Risks of D&C when managing miscarriage

A

Bleeding
Infection
Perforation (1 in 300)
Asherman’s syndrome (1:1000) - less likely with suction curette
GA risks
Small risk of repeat procedure in presence of ongoing
bleeding

368
Q

Most common sites for ectopic pregnancy

A
Tubal (95%)
- Ampullary (55%)
- Isthmic (25%)
- fimbrial (17%)
- Interstitial (2%)
Other (5%)
- Cervical 
- ovarian
- peritoneal
- C-section scar
369
Q

Epidemiology of ectopic pregnancy

A

in developed countries:
Approx 1% of pregnancies are ectopic
(1% of ART pregnancies are heterotopic, 1 in 30,000 spontaneous conceptions are heterotopic)

  • most common in 25-34yo
  • mortality rate in developed countries 0.2%
  • 10% recurrence risk after a single ectopic
370
Q

Risk factors for ectopic pregnancy

A
  • PID (7-fold increased incidence)
  • smoking (impairs tubal motility)
  • tubal surgery
  • previous ectopic pregnancy
  • POP, emergency pill, IUD (lower risk than those NOT on contraception, but higher risk than COCP users as progesterone reduces tubal mobility)
  • ART
  • endometriosis
  • Abnormal embryo
371
Q

Investigations to confirm ectopic pregnancy

A
  • inappropriately rising quant serum bHCG (though up to 1% will have hCG levels <25 therefore neg on UPT_
  • no intrauterine sac seen with HCG levels suggestive that should be visible ultrasonographically (PUL, not confirmed ectopic)
  • fluid in pouch of douglas if ruptured, may have adnexal mass
    Laparoscopy - gold standard for diagnosis
372
Q

At what hCG level should an intrauterine pregnancy be visible on USS

A

TV scan: 1000-1500

TA: 1800-2000

373
Q

Indications for surgical management of ectopic pregnancy

A
  • Significant pain
  • Adnexal mass >35mm
  • fetal activity on USS
  • hCG 5000IU or higher
  • no availability for follow up of medical management
  • maternal preference or seeking permanent contraception
  • subsequent ectopic pregnancy in ipsilateral tube after previous medical management
374
Q

Options for surgical management of ectopic pregnancy

A
  • Salpingectomy (ideally laparoscopic, especially if haemodynamic compromise

Salpingotomy

  • if other risk factors for infertility (i.e. already had other tube removed)
  • 5% risk of persistent ectopic, 20% risk of further treatment, higher rates of recurrent ectopic

Local injection of MTX, KCl or prostaglandins
- high risk of persisting

375
Q

Contraindications for medical management of ectopic pregnancy

A
  • haemodynamic instability
  • fetal cardiac activity
  • hCG >5000
  • mass >35mm
  • no access to emergency facilities within 30 minutes of home
  • heterotopic pregnancy
  • immunodeficiency
  • free fluid in pelvis
  • sensitivity to MTX
    pre-existing liver, haematological, pulmonary or peptic ulcer disease
376
Q

Method of medical management of ectopic pregnancy

A
  • Cease folate supplements
  • 50mg/m2 TBSA methotrexate single dose IM
  • Avoid UV light and high FODMAP foods to avoid side effects
  • paracetamol (+/- NSAIDs if safe)- can get separation pain approx day 3-4
  • quant hCG on day 0(+baseline bloods), 4 and 7
  • if fails to fall more than 15% between days 4 and 7, will need second dose
  • avoid pregnancy for 3 months

Consider if anti-d required (all Rh negative women)

377
Q

Predictors that medical management of ectopic pregnancy will be successful

A
  • lower serum hCG
  • slow-risking plateau or falling hCG prior to treatment
  • falling hCG by day 4
378
Q

Presentation of a female with Kallmann syndrome

A

Delayed or absent puberty with an impaired sense of smell +/- colour blindness

(Autosomal dominant condition, causing GnRH deficiency (hypothalamic hypogonadotrophic hypogonadism)

379
Q

Further defining the cause of hypogonadotrophic hypogonadism

A

GnRH test

  • administer GnRH, if LH response is appropriate = hypothalamic failure
  • if absence of LH response = pituitary failure
380
Q

Causes of abnormal UTERINE bleeding

A

PALM COEI N
PALM = visually objective structural
COEI = unrelated to structural anomalies
N = not yet classified (e.g. AV malformations etc. )

Polyps
Adenomyosis
Leiomyoma (i.e. fibroids)
Malignancy

Coagulopathy
Ovulatory disorders
Endometrial
Iatrogenic

keep in mind women may have NON-uterine causes of vaginal bleeding (urethral, vulvar, vesical, vaginal, cervical and recto-anal)

381
Q

Clinically significant maternal red cell antibodies

A

Anti-D
Anti-c
Anti-kell

Anti-S
Anti-s
Anti-u
Anti-dia
Anti-Coa
382
Q

Acceptable antibody titres for clinically significant maternal red cell antibodies

A

Levels <1:32 are reasonable UNLESS
- >2-fold increase in titre
OR
- Anti-kell antibodies (even low titres are at risk for HDFN)

383
Q

Mechanism for significant fetal/neonatal disease with maternal anti-kell antibodies

A
Suppressed erythropoiesis
PLUS
haemolysis
PLUS
peripheral sequestration of red cells
384
Q

Monitoring pregnancies with clinically significant red cell antibodies

A

4 weekly titres until 28 weeks, then every 2 weeks

If titre >1:32 then needs weekly MCA PSV (through MFM department)

385
Q

Causes for maternal collapse (12)

A

Vasovagal syncope
Postural hypotension
Haemorrhage (PPH, APH, Splenic artery aneurysm rupture, hepatic rupture)
Thromboembolism
Amniotic fluid embolism
Epilepsy
Eclampsia
Intracranial haemorrhage
Cardiac disease (MI, aortic dissection, cardiomyopathy, arrhythmia)
Drug toxicity/overdose (MgSO4, Local anaesthetic, illicit drugs)
Anaphylaxis

386
Q

When should perimortem caesarean section be performed?

A

If there is no response after 4 minutes of correctly performed CPR in a woman >20 weeks

387
Q

Amniotic fluid embolism “cause”

A

Can occur in any trimester
Caused by changes in the normal relationship between the membranes, placenta and uterine wall -> disruption of the integrity of the uterine blood vessels
amniotic fluid/debris is deposited in maternal lungs -> pulmonary vasoconstriction (?anaphylactic-type reaction)

388
Q

Clinical presentation of amniotic fluid embolism

A

Sudden collapse during labour/delivery or immediate postpartum associated with:

  • dyspnoea
  • pink frothy sputum
  • cyanosis
  • Cardiorespiratory failure
  • convulsions (10-20% of cases)

HYPOTENSION
HYPOXIA with respiratory failure
DIC
COMA OR SEIZURES

389
Q

Presentation of regional anaesthesia toxicity

A

Onset almost immediately (within up to 20 mins max) of administering local anaesthetic

  • complain of metallic taste, tinnitus, confusion and disorientation
  • respiratory muscle paralysis and cardiac arrest may occur